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Abstract 
Introduction: Doxorubicin (DOX), is a chemotherapeutic drug that has potent anti-
neoplastic actions. It is for this reason that it remains one of the most widely used 
chemotherapeutic agents that has led to an increase in the survival rates of cancer 
patients. However, DOX’s efficacy in treating a variety of cancers is a double-edged 
sword due to its cumulative, dose-dependent toxicity, particularly in cardiomyocytes. 
Since DOX’s anti-neoplastic activities are separate to the mechanisms underlying its 
toxicity, there is a need to investigate adjuvant therapies that do not interfere with 
DOX’s ability to kill cancerous cells, but have the potential to protect against its toxicity. 
Ghrelin, a brain-peptide commonly known for its appetite inducing and growth 
hormone (GH) releasing actions, has previously been shown to reduce oxidative 
stress, apoptosis, inflammation and fibrosis, all of which contribute to DOX-induced 
toxicity, in different contexts. However, over the years, literature has predominantly 
focused on DOX’s effects on the heart, while very few studies are available regarding 
DOX’s effects on the pancreas. Therefore, this study investigated the effects of DOX 
on the pancreas and whether ghrelin can provide protection against these effects in a 
model of chronic DOX-induced cardiotoxicity.  
Materials and Methods: Male Sprague-Dawley were randomly divided into four 
treatment groups. The vehicle group received 200 μl of physiological saline, the ghrelin 
group received 100 µg/kg three times a week, the DOX group received 2.5 mg/kg once 
a week, and the combination group (DOX+ghrelin) received both treatment regimens. 
All treatments were conducted via intraperitoneal injection over a period of eight 
weeks. A week after the last injection, animals were euthanised, blood was collected, 
and organs were harvested. After the pancreata were weighed, they were non-
specifically divided into two sections, where one half was presevered in 4% 
formaldehyde solution for histological analysis, and the other half was snap frozen in 
liquid nitrogen for biochemical analysis. Serum inflammatory markers as well as 
pancreatic hormones insulin and glucagon were measured using a multiplex assay. 
General morphological changes, collagen deposition, and the number of α- and β-cells 
were assessed by employing H&E, Masson’s Trichrome, and immunohistochemical 
stains, respectively. In addition to lipid peroxidation, oxidative stress was assessed by 
the ORAC, SOD and glutathione assays. Finally, Western blotting was utilised to 
determine the expression of the apoptotic marker, cleaved caspase-3. 
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Results: Following eight weeks of treatment, DOX significantly reduced appetite 
(152.95 ± 10.23 g, p<0.05) and weight gain (186.88 ± 10.35 g, p<0.0001) when 
compared to the saline treated animals. Ghrelin, in the presence of DOX did not 
significantly differ when compared to the DOX treated group. DOX caused significant 
collagen deposition which is an indication of fibrosis in the pancreas of these animals 
(4.80 ± 0.78%, p<0.0001), whereas DOX+ghrelin significantly reduced collagenous 
areas (2.22 ± 0.39%, p<0.001) when compared to the DOX group. Our oxidative stress 
analyses revealed that both the DOX (0.51 ± 0.028 μmol TE/g, p<0.01) and 
DOX+ghrelin (0.47 ± 0.01 μmol TE/g, p<0.05) groups considerably increased their 
anti-oxidant capacity when compared to the vehicle (0.37 ± 0.05 μmol TE/g). 
Moreover, SOD activity was significantly downregulated in both the DOX (1.49 ± 0.18 
U/mg, p<0.01) and DOX+ghrelin (1.54 ± 0.12 U/mg) groups when compared to the 
vehicle. Cleaved caspase 3 was also elevated during DOX treatment but reduced in 
the combination group. No other noteworthy changes were observed in any of the 
other parameters measured. 
Discussion and Conclusion: The results of this study indicate that DOX is a cytotoxic 
agent that induces a loss of appetite and detrimental effects such as oxidative stress, 
fibrosis and cell death in pancreatic tissue. The use of ghrelin as an adjuvant treatment 
in this context was beneficial as weight gain was promoted, while fibrosis and cell 
death were reduced. Although the exact mechanisms underlying ghrelin’s orexigenic 
effects are still unknown, it is believed that ghrelin acts through the hypothalamic-
pituitary axis to promote appetite. Ghrelin’s anti-fibrotic effects are induced through the 
downregulation of pro-inflammatory and pro-fibrotic cytokines, while apoptosis is 
prevented via the inhibition of cytochrome c leakage from the mitochondria. Since 
ghrelin had no effect in improving the activity of SOD, its anti-oxidant effects could not 
be proved in this tissue. In conclusion, while these results shed some light into 
understanding the mechanisms by which ghrelin counteracts DOX’s effects, further 
research is necessary to assess ghrelin’s potential as an adjuvant treatment regimen 
for DOX-induced pancreatic injury. 
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Uittrteksel 
Inleiding: Doksorubisien (DOX), is ‘n chemoterapeutiese middel wat sterk anti-
neoplastiese werking toon. Weens hierdie rede is dit steeds een van die mees 
algemeen chemoterapeutiese middels wat oorlewing in kanker pasiënte verhoog. 
Daarbenewens, is die gebruik van DOX weens die effektiwiteit teen verskeie kankers 
paradoksaal weens die kumulatiewe, dosis-afhanglike toksisiteit veral in 
kardiomiosiete. Omrede DOX se anti-neoplastiese aktiwiteite apart staan van die 
onderliggende toksisiteitsmeganismes, is daar ‘n behoefte om adjuvante terapie te 
ondersoek wat nie met DOX se vermoë inwerk om kankerselle te vernietig nie, maar 
om teen die toksisiteit te beskerm. Grelien, ‘n breinpeptied wat algemeen bekend is 
vir sy aptytinduserende, en groeihormoon (GH) vrystellingseienskappe, is voorheen 
bewys om oksidatiewe stres, apoptose, inflammasie en fibrose, wat bydraes lewer tot 
DOX geïnduseerde tokisisteit, in verskeie kontekse, te verlaag. Geskiedkundig, fokus 
die literatuur meestal op DOX se effek op die hart, terwyl daar min studies die effek 
op die pankreas rapporteer. As gevolg hiervan, het hierdie studie die effekte van DOX 
op die pankreas, en of grelien beskerming kan bied teen hierdie newe-effekte in ‘n 
chroniese DOX geïnduseerde kardiotoksisiteitmodel.  
Materiale en Metodes: Manlike Sprague-Dawley rotte is ewekansig verdeel in vier 
behandelingsgroepe. Die draergroep het ‘n fisiologiese soutoplossing ontvang, die 
grelien groep, 100 µg/kg drie keer per week, die DOX groep, 2.5 mg/kg een keer per 
week, en die kombinasie groep (DOX+grelien) het beide behandelings ontvang. Alle 
behandelings is via intraperitoneale toediening oor ‘n agt-weke periode gedoen. Een 
week na die laaste toediening, is die diere deur middel van eutanasie doodgemaak, 
waarna bloedmonsters versamel, en die organe verwyder is. Nadat die pankrease 
geweeg is, is hulle in twee dele gedissekteer, waar die een helfte met ‘n 4% 
formaldehiedoplossing vir histologiese analiese voorbereid is, en die ander helfte met 
vloeibare stikstof bevries is vir biochemiese analieses. Serum inflammatoriese 
merkers, sowel as pankreatiese hormone en glukagon, is deur middel van ‘n 
multiplekstoetsing gedoen. Algemene morfologiese veranderinge, 
kollageenneerlegging, en aantal α- en β-selle is deur middel van H&E, Masson’s 
Trichrome, en immunohistochemiese kleuring onderskeidelik ondersoek. Addisioneel 
tot lipiedperoksidasie, is oksidatiewe stres deur die ORAC, SOD en glutatioontoetse 
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ondersoek. Laastens, is Westerse kladtegniek gebruik om die uitdrukking van die 
apoptotiese merker, gesplyte kaspase-3 te ondersoek. 
Resultate: Na afloop van die agt-weke behandeling, het DOX betekenisvol aptyt 
verlaag (152.95 ± 10.23 g, p<0.05) asook gewigstoename (186.88 ± 10.35 g, 
p<0.0001) vergeleke met die soutoplossing groep. Grelien, in die teenwoordigheid van 
DOX, het nie aptyt en gewigstoename betekenisvol gestimuleer teenoor die DOX 
groep nie. DOX het ‘n beteknisvolle neerlegging van kollageen in die pankreasse van 
hierdie diere veroorsaak wat aantoon dat fibrose teenwoordig is (4.80 ± 0.78%, 
p<0.0001), terwyl DOX+grelien hierdie kollageenareas verlaag het (2.22 ± 0.39%, 
p<0.001) vergeleke met die DOX groep. Die oksidatiewe stresanalises toon aan dat 
beide DOX (0.51 ± 0.028 μmol TE/g, p<0.01) en DOX+grelien (0.47 ± 0.01 μmol TE/g, 
p<0.05) groepe hulle anti-oksidantkapasiteit verhoog vergeleke met die draer groep 
(0.37 ± 0.05 μmol TE/g). Die SOD aktiwiteit is betekenisvol afgereguleer in beide die 
DOX (1.49 ± 0.18 U/mg, p<0.01) en DOX+grelien (1.54 ± 0.12 U/mg) groepe vergeleke 
met die draer groepe. Gesplyte kaspase-3 is ook verhoog tydens DOX behandeling, 
maar verlaag in die kombinasie groep. Geen ander merkbare veranderinge is 
aangetoon in enige van die ander parameters nie. 
Bespreking en Gevolgtrekking: Die resultate van hierdie studie toon dat DOX ‘n 
sitotoksiese middel is en verlies aan aptyt met skadelike effekte soos oksidatiewe 
stres, fibrose en seldood in pankreatiese weefsel, induseer. Die gebruik van grelien 
as ‘n adjuvante behandelingsmiddel in hierdie konteks was voordelig omrede 
gewigstoename bevorder was, terwyl fibrose en seldood verlaag is. Hoewel die 
presiese meganismes van grelien se oreksigeniese effekte onbekend is, is dit moontlik 
dat grelien deur die hipotalamiese-pituitêre aksis werk en sodoende aptyt bevorder. 
Grelien se anti-fibrotiese effekte word deur die afregulering van pro-inflammatoriese 
en pro-fibrotiese sitokiene bewerk, terwyl apoptose verhoed word via die inhibering 
van sitochroom c lekkasie vanuit die mitochondria. Omrede grelien geen effek op die 
verbetering van SAD aktiwiteit getoon het in die studie nie, kan die anti-oksidant effek 
nie in hierdie weefsel bewys word nie. Gevolglik kan ons wel lig werp op die 
meganismes waarby grelien, DOX se newe-effekte kan teëwerk, maar verdere 
navorsing is nodig om die potensiaal van grelien as ‘n adjuvante terapie vir DOX-
geïnduseerde pankreatiese skade voor te stel.  
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TBARS    Thiobarbituric acid reactive substances 
TBS-T    Tris Buffered Saline-Tween Solution 
TGF-β1   Transforming growth factor-beta1 
TNB     5-thio-2-nitrobenzoic acid 
TNF-α    Tumour necrosis factor-alpha 
UV     Ultra-violet  
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Unit of Measurements 
%     Percentage  
°C     Degrees 
µg     Microgram 
µl     Microlitre  
µm     Micrometre  
µmol     Micromole 
μM     Micromolar  
AU     Arbitrary units 
cm     Centimetre  
g     Relative centrifugal force   
g     Gram 
kDa     Kilodalton  
kg     Kilogram  
l     Litre 
M     Molar  
mg     Milligram 
ml     Millilitre   
m2     Metres-squared  
nm     Nanometre  
mM     Millimolar  
pg     Picogram 
rpm     Revolutions per minute 
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V     Voltage  
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CHAPTER 1: Literature Review 
1.1 Embryology and structure of the pancreas 
During early human development, both the dorsal and ventral buds originate from the 
endodermal lining of the primitive foregut tube and contribute to the formation of the 
pancreas (El-Gohary & Gittes, 2012). As the duodenum rotates to become C-shaped, 
the ventral bud follows to eventually lie below and fuse with the dorsal bud. The ventral 
bud forms the uncinate process of the pancreas as well as the inferior portion of the 
head, while the dorsal bud forms the remaining part of the head, as well as the tail and 
body of the pancreas (Sadler & Langman, 2006). Both the endocrine and exocrine 
tissue of the pancreas develop simultaneously from the two buds, in which the 
pancreatic precursor cells appear to have plasticity and can differentiate into either 
endocrine cells or exocrine cells during development (Tsuchitani et al., 2016). The 
human pancreas is a compact organ that is located in the upper region of the 
abdomen. It is located posterior to the stomach, and lies between the duodenum and 
the spleen (Figure 1.1) (Moore et al., 2008). 
 
 
 
 
 
 
 
 
 
Figure 1.1: The location of the human pancreas relative to other organs in the body. 
The pancreas is situated posterior to the stomach and lies between the duodenum and the 
spleen. Sections include the tail, body, neck, head and uncinate process. Adapted from Drake 
et al. (2010).  
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Interestingly, the rat pancreas is classified as an intermediate of the human pancreas 
where the splenic part is relatively compact, and the duodenal part is found to be 
dispersed within the mesentery. Although much controversy exists regarding the 
identification of the different parts of the rat pancreas, the regions of the rat pancreas 
can be identified based on the anatomy of the human pancreas. The duodenal section 
(derived from the ventral bud) and para-biliary section (derived from the dorsal bud) 
are situated near the duodenum and form the head of the pancreas. The gastric and 
splenic sections (both derived from the dorsal bud) are situated between the head of 
the stomach and spleen and form the body of the pancreas, and thus the terminal end 
of the splenic section is situated near the hilum of the spleen and forms the tail of the 
pancreas (Figure 1.2) (Elayat et al., 1995; Tsuchitani et al., 2016)  
 
 
 
 
 
 
 
Figure 1.2: An illustration of the rat pancreas in its position relative to the spleen and 
the gut. The pancreas is situated between the spleen, the stomach and the duodenum. 
Abbreviations: S (Splenic section); D (Duodenal section); P (Parabiliary section); G (Gastric 
section). Adapted from Tsuchitani et al. (2016).   
The exocrine tissue consists of lobular acini and ducts that are enclosed in a capsule 
and held together by connective tissue (Wieczorek et al., 1998). The acinar and duct 
cells in the exocrine tissue secrete pancreatic digestive juices into the duodenum of 
the stomach (Moore et al., 2008). In contrast, the endocrine tissue consists of the islets 
of Langerhans that are not enclosed in a capsule but are embedded in collagen fibres 
(Wieczorek et al., 1998). The islets of Langerhans consist of four different cell types: 
insulin-secreting beta (β)-cells, glucagon-secreting alpha (α)-cells, somatostatin-
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secreting delta ( )-cells, and pancreatic polypeptide (PP)-secreting cells. These cells 
secrete the pancreatic hormones into the bloodstream. The arrangement of these cells 
within the pancreas is, however, species specific and is believed to have a significant 
influence on pancreatic function (Elayat et al., 1995; Hauge-Evans et al., 2009). 
1.2 Composition and distribution of cells in both the human and rat endocrine 
pancreas 
In the human pancreas the islets consist of ±54% β-cells, ±35%, α-cells, ±10% δ-cells, 
and  less than 1% of PP-cells (Wieczorek et al., 1998; Brissova et al., 2005; Steiner et 
al., 2010). Erlandersen et al. (1976) demonstrated that human islets contain a central 
β-cell core surrounded by α-, δ-, and PP-cells, while Brissova et al. (2005) and Cabrera 
et al. (2006) indicated that the four cell types are in fact randomly arranged and 
dispersed within the islets. In addition, it has previously been shown that smaller islets 
have a β-cell core surrounded by α-, δ- and PP-cells, while larger islets have α-, δ- 
and PP-cells in the core surrounded by β-cells (Bosco et al., 2010; Farhat et al., 2013). 
Based on the above mentioned studies, it is clear that there is still some controversy 
around the location of these cells within the islets. Regarding the islet composition 
between different regions of the pancreas, reports are conflicting. Some studies 
indicate that the head and uncinate process are richer in PP-cells, while the tail portion 
is richer in β- and α-cells (Gersell et al., 1979; Elayat et al., 1995). However, Wieczorek 
et al. (1998) reported no differences between islet density of δ- and PP-cells 
throughout the pancreas, and Cabrera et al. (2016) more recently reported no changes 
in islet composition between regions, except that α-cells are more abundant in the 
neck. When comparing the human and rodent pancreas, the human pancreas is 
described as having less β-cells and more α-cells than the rodent pancreas (Kim et 
al., 2009; Steiner et al., 2010). 
Rodent islets are composed of 60-85% β-cells, 15-25% α-cells, 6-10% δ-cells and less 
than 1% of PP-cells (Brissova et al., 2005; Steiner et al., 2010). In contrast to human 
islets, rat islets are extensively and consistently described in the literature as having a 
central β-cell core surrounded by a mantle consisting of α-, δ- and PP-cells (Zafar & 
Mughal, 2002; Brissova et al., 2005; Cabrera et al., 2006; Kim et al., 2009). The 
majority of the mantle is made up of α-cells, while δ-cells are located in the periphery 
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either between the α-cells, or between the β- and α-cells. The PP cells are found either 
isolated or in small clusters in the periphery of islets (Erlandersen et al., 1976; 
Wieczorek et al.,1998). With regards to the composition of rodent islets between 
different regions of the pancreas, α- and PP-cells are indicated to be more abundant in 
the head section, while β- and δ-cells are more abundant in the tail section (Elayat et al., 
1995; Zafar & Mughal, 2002).  
1.3 The functional role of the pancreas 
The differences between species in terms of islet structure may be a result of the 
variation in the mechanisms involved in the development of the pancreas. However, 
both metabolic and physiological conditions are suspected to have a greater influence 
in defining the structure of the islets. In vivo experimental models have shown that 
conditions such as pregnancy and obesity can alter the structure of islets and increase 
β-cell mass (Steiner et al., 2010). As previously mentioned, exocrine cells produce 
pancreatic digestive juices consisting of pancreatic enzymes produced and stored in 
secretory vesicles (known as zymogens) in the acinar cells, and an aqueous alkaline 
solution secreted by duct cells lining the pancreatic ducts. Following gastric digestion, 
duodenal acidification and entry of fatty acids or bile trigger the release of secretin 
hormone from the duodenal mucosa, while vagal stimulation and entry of fatty acids 
or amino acids trigger the mucosa to release the cholecystokinin (CCK) hormone. 
Secretin stimulates duct cell secretion and CCK stimulates exocytosis of pancreatic 
enzymes in acinar cells. These digestive juices travel through the pancreatic ducts 
and enter the duodenum via the major duodenal papilla (main pancreatic duct 
opening) or minor duodenal papilla (accessory duct opening) (Moore et al., 2008; 
Steer, 2012; Puri et al., 2015). The proteolytic enzymes (trypsinogen, 
chymotrypsinogen and procarboxypeptidase) are responsible for the breakdown of 
protein into amino acids and are secreted in their inactive forms. Enterokinase within 
the duodenum converts trypsinogen into active trypsin, which is then responsible for 
converting chymotrypsinogen and procarboxypeptidase into active chymotrypsin and 
carboxypeptidase, respectively. Amylase is responsible for the breakdown of 
carbohydrates or starch into glucose, and pancreatic lipase breakdown triglycerides 
(fats) into fatty acids and monoglycerides. In addition, bile produced by the gallbladder 
enters the duodenum through the major duodenal papilla where it emulsifies large fat 
molecules into smaller droplets, which are easier for lipase to digest (Sherwood, 2001; 
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Kaurich, 2008, Moore et al., 2008). Figure 1.3 below illustrates a coronal section 
through the human pancreas. 
 
 
 
 
 
 
 
 
 
Figure 1.3: Exocrine and endocrine cells of the human pancreas. The exocrine pancreas 
secretes digestive juices into the duodenum which are composed of an aqueous alkaline 
solution secreted by the ductal cells and digestive enzymes secreted by the acinar cells. The 
endocrine pancreas (islets of Langerhans) secretes pancreatic hormones into the blood. 
Adapted from Sherwood (2001).  
The islets of the pancreas produce and secrete the pancreatic hormones insulin, 
glucagon, somatostatin and PP. It is well known that insulin and glucagon regulate the 
body’s blood glucose levels. While insulin secretion is primarily stimulated by glucose, 
it can also be stimulated by amino acids, other hormones and certain drugs (Robertson 
& Harmon, 2007; Puri et al., 2015). Glucose enters β-cells via glucose transporter 2 
(GLUT-2) and is metabolised into adenosine triphosphate (ATP), which consequently 
depolarises β-cells, causing calcium (Ca2+) to enter the cell and promote exocytosis 
of insulin. Insulin increases the uptake of glucose, fatty acids and amino acids from 
the blood into the liver, skeletal muscles and adipocytes (Sherwood, 2001; Steer, 
2012). When circulating levels of blood glucose reach abnormally low levels, insulin 
secretion ceases in order to prevent hypoglycaemia, which then triggers the secretion 
of glucagon (Robertson & Harmon, 2007; Hauge-Evans et al., 2009). Glucagon is 
secreted in the post-absorptive state and mainly targets the liver, where it causes 
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increased glycogenolysis (glycogen breakdown) and gluconeogenesis (glucose 
production) via the cyclic adenosine monophosphate (cAMP) second messenger 
pathway, ultimately resulting in increased blood glucose levels. In addition, glucagon 
also leads to increased blood fatty acid levels by accelerating lipolysis (breakdown of 
adipocytes) (Sherwood, 2001; Jiang and Zhang, 2003; Rafacho et al., 2014). The 
dysregulation of insulin and glucagon secretion is associated with both Type I and II 
diabetes. Type I diabetes is an autoimmune disease causing β-cell destruction and is 
associated with a low plasma insulin to glucagon ratio, promoting hyperglycaemia. 
Type II diabetes is associated with increased plasma concentrations of both insulin 
and glucagon, where over stimulation of insulin secretion as well as toxic glucose 
levels can cause damage to β-cells and patients may require insulin therapy (Steer, 
2012). 
Somatostatin is mainly produced and secreted by the gastrointestinal system, with the 
neuroendocrine cells of the central nervous system contributing a small portion 
(Hauge-Evans et al., 2009). This hormone has a variety of functions within the body 
and can be secreted into the blood, synaptic clefts, and intercellular spaces (Arimura 
& Fishback, 1981). For the most part, somatostatin inhibits endocrine systems by 
suppressing growth hormone (GH) release from the anterior pituitary in the 
hypothalamus (Hauge-Evans et al., 2009). In addition, somatostatin secreted by gut 
δ-cells inhibits the digestion of nutrients in the stomach, causing a decrease in nutrient 
absorption (Sherwood, 2001). Although δ-cells make up only a small portion of the 
islets, somatostatin produced by these cells influences glucose homeostasis. In 
contrast to the effects of insulin and glucagon within the body, somatostatin within the 
pancreas does not act on other organs. Rather, it inhibits both insulin and glucagon 
secretion through its paracrine effects, whereby both β-cells and α-cell express 
somatostatin receptors (Arimura & Fishback, 1981; Robertson & Harmon, 2007; 
Hauge-Evans et al., 2009; Rafacho et al., 2014). Since other organs produce the 
majority of somatostatin, pancreatic diseases are generally not associated with 
dysregulation of somatostatin (Steer, 2012) 
PP is not only secreted by PP-cells of the islets, it is also released into circulation by 
the small and large intestines. PP has a wide variety of effects on the gastrointestinal 
tract, such as gastric motility, gallbladder contraction and stimulating secretion by 
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pancreatic islet cells (Wook et al., 2014). Low PP plasma levels are reported in obese 
patients, whereas high levels are reported in patients suffering from anorexia nervosa 
(Lassmann et al., 1980; Uhe et al., 1992). This is because PP suppresses both food 
intake and gastric emptying while increasing energy expenditure, thereby creating a 
negative energy balance (Sherwood, 2001; Kojima et al., 2007). This is achieved by 
PP inhibiting vagal nerve activity, as well as suppressing expression of both the 
feeding-stimulatory neuropeptides within the hypothalamus (involved in regulating 
food intake and body weight) and the gastric peptide ghrelin (involved in stimulating 
the appetite) (Asakawa et al., 2003). PP has the highest affinity for the neuropeptide 
Y4 (NPY4) receptor. This receptor is expressed in many organs, including the 
gastrointestinal tract, pancreas and hypothalamus, which further highlights its 
importance in regulating food intake. Recently, Wook et al. (2014) showed that apart 
from all somatostatin-containing cells in the nervous system, the NPY4 receptor is only 
expressed by the somatostatin-secreting δ-cells in the pancreas. This study illustrated 
that human islets treated with PP increased insulin secretion. Since NPY4 receptors 
are only expressed on δ-cell and somatostatin is a known inhibitor of insulin secretion, 
it is thought that PP acts by inhibiting δ-cell secretion, ultimately alleviating the 
inhibition of insulin secretion.  These functions highlight the vital role of the pancreas 
in maintaining glucose homeostasis, producing and secreting critical digestive juices, 
and regulating the gastrointestinal tract during digestion. However, similar to other 
organs, the pancreas can be damaged by different stressors, including drugs such as 
Doxorubicin (DOX), a potent chemotherapeutic agent.   
1.4 Doxorubicin 
DOX forms part of a class of anti-cancer drugs known as anthracyclines (Misiti et al., 
2003), and together with Daunorubicin (DNR), was among the first anthracyclines to 
be discovered. In 1958, the anthracycline antibiotic DNR was isolated from a red 
pigment-producing bacterium Streptomyces peucetius in the south-eastern part of 
Italy and was found to display anti-tumour effects. It was only in 1969, near the Adriatic 
Sea, that DOX was isolated from a mutant of the original Streptomyces species, which 
explains DOX’s alternative name (Adriamycin). DOX is currently commercially 
available and is produced by the Streptomyces peucetius subspecies caesius (Weiss, 
1992; Lomovskaya et al., 1999; Misiti et al., 2003). 
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While DNR is highly effective in treating both acute lymphoblastic leukaemia and acute 
myeloblastic leukaemia, DOX, in addition to being highly potent against 
haematological malignancies, has been shown to be effective in treating a wide range 
of tumours, including breast cancer, sarcomas, lymphomas, as well as childhood 
malignancies (Minotti et al., 2004; Štěrba et al., 2011). DOX has been shown to be 
greatly effective against cancerous cells with a high proliferation rate (Yi et al., 2006), 
and as such there are only a very few cancers that DOX is ineffective in treating 
(Weiss, 1992). Therefore, DOX remains the most widely used chemotherapeutic drug. 
Although effective, DOX has significant off-target toxicity, particularly in 
cardiomyocytes (Gewirtz, 1999). 
1.4.1 Classification of Doxorubicin-induced cardiotoxicity 
Cardiotoxicity is a well-known side effect of anthracycline treatment and refers to the 
damage induced on the heart by toxic substances, causing impaired cardiovascular 
function (Moulin et al., 2015). DOX and DNR are among the most potent cardiotoxic 
agents, which have been shown to lead to the development and progression of heart 
failure in cancer survivors, and more so in patients with pre-existing heart disease, the 
elderly and children (Ghigo et al., 2016). 
Cardiotoxicity can be classified into three main categories, namely acute, chronic and 
delayed-onset cardiotoxicity. Acute toxicity occurs during or within a few minutes 
following DOX administration. Signs and symptoms of this form include cardiac 
arrhythmias, sinus tachycardia and electrocardiogram (ECG) alterations, which can 
last over 24 hours. These symptoms are minor and clinically manageable (Singal et 
al., 1997; De Beer et al., 2001; Barrett-Lee et al., 2009; Octavia et al., 2012). Chronic 
cardiotoxicity may occur within weeks,  months or years after a patient’s last dose of 
DOX, in which symptoms include dilated cardiomyopathy and decreased left 
ventricular ejection fraction that may eventually lead to chronic heart failure (Von Hoff 
et al., 1979; Singal et al., 1997; De Beer et al., 2001; Octavia et al., 2012). Delayed-
onset cardiotoxicity may occur years to decades after DOX treatment. Although the 
clinical symptoms are not well defined in the literature, it is known that dilated or 
restrictive cardiomyopathy, as well as myocardial arrhythmias are clinical symptoms 
of delayed-onset cardiotoxicity (Bernaba et al., 2010). This form of cardiotoxicity 
clinically manifests in patients over many years and is triggered by cardiovascular 
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stress, such as viral infections and pregnancy (Ali et al., 1994; Sereno et al., 2008). 
Additionally, delayed-onset cardiotoxicity has been described to occur mostly in 
childhood cancer survivors (Leandro et al., 1994; Lipshultz et al., 2008). Therefore, 
although DOX is an effective chemotherapeutic agent and has led to the increased 
survival rate of childhood cancer patients, there is an  increased risk of these patients 
developing chronic cardiotoxicity (Harake et al., 2012; Ezquer et al., 2015). 
Both chronic and delayed cardiotoxicity are dose dependent and result in detrimental 
changes that are often irreversible (Gewirtz, 1999; Misiti et al., 2003; Oliveira et al., 
2013). When administered intravenously to cancer patients, the distribution half-life of 
DOX in the plasma is between 3 - 5 minutes, highlighting DOX‘s rapid uptake into 
cells, while its terminal half-life is between 24 – 36 hours, suggesting that DOX takes 
a longer time to be eliminated from tissues (Zheng et al., 2006). The incidence of DOX-
induced cardiotoxicity rapidly increases above the cumulative dose of 550 mg/m2, 
thus, the recommended lifetime cumulative dose of DOX for cancer patients ranges 
between 450 – 500 mg/m2 (Von Hoff et al., 1979; Yeh et al., 2009; Warpe et al., 2015). 
Although reducing the cumulative dose of DOX has been shown to reduce acute 
cardiotoxicity, there has been no significant decrease in late-onset cardiac 
complications reported, thus, there is no established dose of DOX deemed reasonably 
safe (De Angelis et al., 2016). As such, the leading cause of death amongst cancer 
survivors is now cardiovascular disease (Ghigo et al., 2016).  
While major efforts have been made to produce anthracycline analogs that are less 
toxic to the heart, only a few have been approved for clinical use (Figure 1.4). The 
chemical structures of DOX and DNR are almost identical. Both contain an aglyconic 
moiety (known as doxorubicinone), consisting of tetracyclic rings that contain quinone-
hydroquinone moieties, and a sugar moiety (known as daunosamine), which is 
attached by a glycosidic bond at carbon number 7 (C7). The difference between these 
analogs is that the side chain of DOX ends with a primary alcohol, while DNR ends 
with a methyl group (Minotti et al., 2004; Sies & Packer, 2004). Although minor, these 
structural differences play a major role in the efficacy of these two drugs against 
cancerous cells. Epirubicin (EPI) is a semi-synthetic derivative of DOX, where the 
hydroxyl group at carbon number 4 (C4) in the sugar moiety undergoes a positional 
change. Idarubicin (IDA) is derived from DNR, in which the 4-methoxy group is 
removed at C4 in the doxorubicinone moiety. Although EPI and IDA have been 
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clinically approved and have been used as alternative chemotherapeutic agents to 
DNR and DOX in the clinical setting, they are less potent in killing cancerous cells than 
DNR and DOX and are also cardiotoxic (Minotti et al., 2004; Šimůnek et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The chemical structures of DOX and is derivatives. The chemical structures 
of the four anthracycline analogs used in the clinical setting. Anthracyclines are composed of 
an aglyconic moiety, consisting of tetracyclic rings (indicated as A-D) that contain quinone-
hydroquinone moieties (indicated by red circles). The sugar moiety is attached by a glycosidic 
bond to the aglyconic moiety at C7. The difference in these analogs are in the side chains 
(indicated by orange arrows). Abbreviations: DOX (Doxorubicin), DNR (Daunorubicin), EPI 
(Epirubicin), IDA (Idarubicin), C7 (carbon number 7). Adapted from Minotti et al. (2004).  
1.5 Doxorubicin’s mechanism of action 
The mechanisms by which DOX kills cancer cells are different to the mechanisms 
involved in cardiotoxicity (Myers, 1998), therefore this review will only focus on the 
cardiotoxic effects of DOX. It should be noted that the exact underlying mechanisms 
involved are yet to be fully elucidated.  
 
Sugar moieties 
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1.5.1 Doxorubicin-induced oxidative stress 
The most common and frequently reported mechanism of DOX-induced cardiotoxicity 
is the generation of free radicals including reactive oxygen species (ROS), which 
causes oxidative stress and oxidative damage. Oxidative stress is a physiological 
condition that results when the balance between free radicals and anti-oxidants in the 
cell is disturbed, and the generation of free radicals exceeds the ability of anti-oxidants, 
leading to oxidative damage (Asensi et al., 1999; Mizutani et al., 2003, Rahman, 
2007). DOX can generate free radicals in two ways, either via enzymes in the 
mitochondrial respiratory chain, or via enzyme-independent pathways involving 
transition metals such as iron (Fe). Since DOX contains both quinone and 
hydroquinone moieties within its structure (Figure 1.4), it can be both oxidised and 
reduced to generate free radicals (Figure 1.5). More specifically, the quinone residue 
of DOX is reduced by oxidoreductases in the mitochondria, namely mitochondrial 
reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase (Davies & 
Doroshow, 1986), NAD(phosphate) (NADPH)-dependant carbonyl reductase (Olson 
et al., 1988), complex I of the mitochondrial respiratory chain (Goormaghtigh et al., 
1987), and membrane-bound cytochrome P450 reductase (Kostrzewa-Nowak et al., 
2005). This process occurs via a one-electron transfer in the presence of NAD(P)H to 
form the semiquinone radical. In the presence of oxygen (O2), the semiquinone radical 
donates its unpaired electron to form superoxide radicals (O2●−), which are dismutated 
by superoxide dismutase (SOD) to form hydrogen peroxide (H2O2). The semiquinone 
radical can also react with H2O2 to form hydroxyl radicals (OH●) that can damage 
deoxyribonucleic acid (DNA), proteins and lipids. Alternatively, the semiquinone 
radical is able to accept electrons back, regenerating the DOX parent structure. This 
series of reactions is termed “redox cycling” and emphasises the fact that a small 
concentration of DOX is able to generate large amounts of free radicals (Goodman & 
Hochstein, 1977; Kalyanaraman et al., 2002; Minotti et al., 2004). 
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Figure 1.5: The proposed mechanisms involved in DOX-induced oxidative stress. DOX 
can generate free radicals in two ways, either via enzymes in the mitochondrial respiratory 
chain (indicated in green arrows), or via enzyme-independent pathways involving transition 
metals such as iron (Fe) (indicated in blue arrows). These free radicals cause damage to DNA, 
proteins and lipids within cells. Abbreviations: DOX (Doxorubicin), NAD(P)H (reduced 
nicotinamide adenine dinucleotide (phosphate)), NAD(P)+ (oxidised NAD(P)H), H+ (proton), O2 
(oxygen), O2●− (superoxide radicals), H2O2 (hydrogen peroxide), OH● (hydroxyl radicals), Fe3+ 
(ferric ion), Fe2+ (ferrous iron). 
The second way that DOX can generate free radicals is via non-enzymatic pathways 
involving Fe. O2●− generation by DOX is able to release Fe from Fe-containing centres 
of molecules, causing an increase in intracellular free Fe levels. DOX is able to chelate 
Fe and form complexes, which in turn react with O2 to form ROS, contributing to 
oxidative stress (Beckman & Ames, 1998; Ghigo et al., 2016). The Fe-catalysed 
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Haber-Weiss reaction is a two-step process, in which the first step of the reaction 
involves the reduction of ferric ion (Fe3+) to ferrous ion (Fe2+). The second step of the 
reaction, known as the Fenton reaction, involves the reaction of this newly formed Fe3+ 
and H2O2  to form the highly toxic OH● (Bredehorst et al., 1987) (Figure 1.5). In 
addition, H2O2 can combine with free Fe to form perferryl iron (FeIV=O), in which both 
OH● and FeIV=O are potent oxidants that cause irreversible cell damage by inactivating 
key proteins and enzymes located within the sarco(endo)plasmic reticulum (ER) and 
mitochondrial respiratory chain (Keizer et al., 1990; Kalyanaraman et al., 2002; 
Šimůnek et al., 2009).  
Additionally, free intracellular Fe levels are tightly regulated by the storage molecule, 
ferritin, and the receptor, transferrin, both of which play a role in controlling the 
interaction between iron-regulatory proteins (IRPs) and specific iron-responsive 
elements (IREs) located within genes (Šimůnek et al., 2009; Montaigne et al., 2012). 
The formation of DOX-Fe complexes reduces the amount of free Fe that is available 
to bind to IRPs. Therefore, IRPs sense a decrease in intracellular free Fe and respond 
by binding to IREs. Ferritin expression is downregulated and transferrin receptors are 
upregulated, resulting in increased free Fe levels. However, this consequently means 
that more Fe is available to bind to DOX, contributing to free radical generation and 
subsequent cellular damage (Kalyanaraman et al., 2002; Montaigne et al., 2012, 
Ghigo et al., 2016).  
1.5.2 Doxorubicin-induced cell death 
Apoptosis is a form of programmed cell death (cellular suicide) that is a crucial 
physiological process responsible for removing damaged, redundant and mutated 
cells from tissues. Dysregulation of apoptosis in cells can lead to pathophysiological 
disorders (Jones & Gorges, 1997; Ellerby & Bredesen, 2000). Apoptotic signals 
include oxidative stress and cytotoxic agents such as DOX, where studies have 
demonstrated DOX-induced cell death as a result of oxidative stress in endothelial 
cells and cardiomyocytes (Sawyer et al., 1999; Kotamraju et al., 2000). This can occur 
as a result of DOX’s ability to activate both the extrinsic and intrinsic apoptotic 
pathways (Figure 1.6). DOX can initiate apoptosis both indirectly and directly through 
ROS generation and by inducing mitochondrial leakage of cytochrome c, respectively 
(Lee et al., 2002; Nitobe et al., 2003; Tsang et al., 2003; Kim et al., 2006; Zhang et al., 
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2012). The extrinsic apoptotic pathway, or death receptor pathway, involves the 
activation of pro-apoptotic ligands and cell surface receptors (Crompton, 2000). The 
binding of death ligands to cell receptors from the tumour necrosis factor (TNF)-
receptor family results in the proteolytic activation of caspases, the executioners of 
apoptosis and inter-nucleosomal DNA fragmentation (Nagata, 1997). One of the most 
important regulators of the extrinsic apoptotic pathway in many organisms is the 
Fas/Fas ligand system, in which Fas is a member of the TNF-receptor family that is 
expressed in a variety of tissues. The binding of Fas ligand to the Fas receptor results 
in the formation of a homotrimetric complex that recruits the Fas-associated death 
receptor domain (FADD), ultimately leading to the activation of caspases downstream 
(Yonehara, 1989; Suda et al., 1993; Nagata, 1997; Tolosa et al., 2005). Studies 
investigating DOX-induced toxicity have reported overexpression of Fas ligand and 
high levels of TNF-α in cardiomyocytes suggesting induction of the extrinsic apoptotic 
pathway (Krown et al., 1996; Nakamura et al., 2000; Gustafsson & Gottlieb, 2003). 
The intrinsic apoptotic pathway is characterised by the release of cytochrome c from 
the mitochondria, which enters the cytosol and activates caspases (Crompton, 2000). 
This release is triggered by mitochondrial depolarisation which can occur either via B-
cell lymphoma 2 associated X protein (Bax) and Bax/Bcl-2 homologous 
antagonist/killer (Bak) activation, or opening of the mitochondrial permeability pore 
(mPTP). Bax and Bad are pro-apoptotic proteins located in the cytosol. Following 
stress signals, these proteins undergo conformational changes and form a pore in the 
outer mitochondrial membrane, subsequently depolarising the mitochondria. Both 
ROS and increased intra-mitochondrial Ca2+ can stimulate opening of the mPTP. 
Cytochrome c in the cytosol forms an apoptosome complex with apoptosis protease 
protein-1 (Apaf-1) and caspase-9, leading to the proteolytic activation of caspase-3 
(Tsujimoto, 1998; Minotti et al., 2004; Saelens et al., 2004; Kim et al., 2006; Parrish et 
al., 2013). Caspase-mediated apoptosis is accomplished through the cleavage of 
several cell survival proteins, where activated caspase-3 cleaves poly (adenosine 
diphosphate-ribose) polymerase-1 (PARP-1), a nuclear enzyme involved in DNA 
repair and transcriptional regulation (Kaufmann et al., 1993; Tewari et al., 1995; 
Fischer et al., 2003; Poirier et al., 2002; Chaitanya et al., 2010). Additionally, activation 
of tumour suppressor protein p53 has also been implicated to induce apoptosis. p53 
is responsible for the upregulation of genes involved in DNA repair and cell cycle 
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arrest, and in conditions where oxidative stress levels are high, p53 augments Bax 
(pro-apoptotic) and attenuates Bcl-2 (anti-apoptotic), thereby inducing apoptosis 
(Minotti et al., 2004; Yee & Vousden, 2005; Kim et al., 2006; Liu et al., 2008).  
It is believed that DOX’s ability to activate the intrinsic apoptotic pathway occurs as a 
result of DOX binding to, and depolarising, the mitochondria. It is well known that DOX 
has a high affinity for cardiolipin, a phospholipid involved in the maintainance of the 
electro-chemical gradient of the electron transport chain during ATP synthesis 
(Goormaghtigh et al., 1990; Harake et al., 2012). This phospholipid is closely 
associated with the inner mitochondrial membrane and is required for optimal activity 
of oxidative phosphorylation complexes. In addition, ROS can cause oxidation of 
cardiolipin, triggering the release of cytochrome c into the cytosol either through the 
mPTP or Bax/Bak pore (Kim et al., 2006; Pereira et al., 2011; Zhang et al., 2012; 
Paradies et al., 2014). Interestingly, although free radicals, particularly H2O2, 
contribute to the opening of mPTP, studies show H2O2 formation precedes both the 
loss of mitochondrial membrane integrity and caspase-3 activation during DOX-
mediated apoptosis (Kroemer et al., 1997; Hampton et al., 1998; Chandra et al., 2000; 
Mizutani et al., 2005).  
It was initially believed that DOX only indirectly induced apoptosis through ROS 
generation (Wang et al., 2002; Nitobe et al., 2003), however, it has since been 
demonstrated that DOX can in fact initiate apoptosis directly by stimulating the opening 
of Ca2+ channels (Zorzato et al., 1985) and inhibiting the sodium-calcium (Na+/Ca2+) 
exchanger (Caroni et al., 1981) on the ER, resulting in disruption of Ca2+ homeostasis 
(Kim et al., 2006; Octavia et al., 2012; Zhang et al., 2012). This results in an increase 
in cytosolic Ca2+ concentration, which in itself promotes ROS formation through Ca2+-
sensitive ROS-generating enzymes (Zhang et al., 2009). Since the ER is closely 
associated with mitochondria, the intra-mitochondrial Ca2+ levels rise, stimulating 
mPTP opening (Olson et al., 1974; Brookes et al., 2008; Williams et al., 2013).  
However, the type of cell death that results from DOX treatment depends on both the 
dosage and duration of treatment (Tacar et al., 2013). Since cardiolipin is involved with 
the electron transport chain and ATP production, DOX can interfere with these 
processes. With depletion of ATP and mPTP opening, the structural and functional 
integrity of the cell cannot be maintained, resulting in mitochondrial swelling, 
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irreversible cellular damage and ultimately, necrotic cell death (Montaigne et al., 
2012). Necrotic cell death is an uncontrolled process, characterised by disruption of 
the cell membrane, reduced ATP, and cell swelling (Gustafsson & Gottlieb, 2003). 
Considering all of the above, it is clear that DOX is a toxic agent that causes major 
damage to the cell and its organelles and thus similar events are likely to occur in the 
pancreas, however, there is a lack of studies investigating this.  
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Figure 1.6: Doxorubicin-induced apoptosis through both the intrinsic and extrinsic 
apoptotic pathways. DOX initiates the extrinsic apoptotic pathway (indicated with black 
arrows) via the death receptor pathway (such as Fas/FasL system). Binding of FasL to its 
receptor ultimately leads to the activation of the caspases downstream. DOX can initiate the 
intrinsic apoptotic pathway (indicated with light blue arrows) through ROS generation, which 
affects Ca2+ homeostasis within the ER and activates the tumour suppressor protein p53, 
leading to opening of the mPTP, Cyt c leakage, and activation of caspases. Abbreviations: 
DOX (Doxorubicin), ROS (reactive oxygen species), Bax (Bcl-2 Associated X protein), Bcl-2 
(B-cell lymphoma family protein 2), FasL (Fas ligand), Fas (Fas receptor), FADD (Fas 
associated protein with death domain), ER (sarco(endo)plasmicreticulum), mPTP 
(mitochondrial permeability transition pore), Cyt c (cytochrome c), Apaf-1 (apoptosis protease 
protein-1), Cleaved-PARP-1 (cleaved-poly (adenosine diphosphate-ribose) polymerase-1), 
round arrow head (inhibits),  (leads to),↑ (increases), ↓ (decreases). 
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1.6 Pancreatic cell death and inflammation    
The type of cell death that occurs during pancreatic cell injury can influence the extent 
of inflammation. Pancreatitis is an inflammatory disorder of the pancreas resulting from 
acinar cell damage and can be classified as acute or chronic. Acute pancreatitis is 
associated with leakage of pancreatic digestive enzymes from acinar cells, while 
chronic pancreatitis is associated with atrophy of acinar cells and fibrotic replacement 
of organ architecture (Jones & Gorges, 1997). The severity of inflammation is directly 
proportional to the extent of necrosis and inversely proportional to the extent of 
apoptosis in the acinar cells  (Kaiser et al., 1995) (Figure 1.7). The magnitude of 
necrosis is dependent on neutrophil recruitment to the pancreas following injury, where 
neutrophils can shift acinar cell death from apoptosis to necrosis  (Sandoval et al., 
1996). This limits neutrophil recruitment to the site of injury, and thereby prevents the 
shift from apoptosis to necrosis which could potentially ameliorate the severity of 
pancreatitis (Jones & Gorges, 1997).  
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Apoptotic or necrotic cell death of acinar cells in the pancreas. During 
pancreatic injury, apoptotic cell death is associated with reduced tissue damage and mild 
inflammation, while necrotic cell death is associated with neutrophil infiltration and severe 
inflammation. Adopted from Jones & Gorges (1997).  
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1.6.1 Causes and mechanisms involved in pancreatitis 
Acute pancreatitis has been associated with pancreatic duct obstruction (by 
gallstones, or Ca2+ granules and muco-glycoproteins), alcohol abuse, idoipathic 
factors (in which the cause is unknown and could be related to anatomical 
abnormalities or metabolic disturbances) and other factors (including certain drugs). 
However, the pathophysiology underlying drug-induced pancreatitis is yet to be 
established (Salvador et al., 2014; Granger & Remick, 2005; Matull et al., 2006; 
Bachmann et al., 2011; Lankisch et al., 2015). 
Irrespective of the mechanism, obstruction or damage to pancreatic ducts can hinder 
exocytosis of digestive enzymes contained in zygomens within acinar cells. These 
zygomen vesicles consequently merge with cellular lysosomes and form autophagic-
like vacuoles that contain both digestive and lysosomal enzymes. The lysosomal 
enzyme, cathepsin B, is able to activate trypsin, subsequently leading to the activation 
of other digestive enzymes. These vacuoles are released into the intersitial spaces 
and cause auto-digestion of pancreatic tissue, leading to consequent pancreatic injury 
and stimulation of the inflammatory response (Jones & Gorges, 1997; Kaurich, 2008). 
Furthermore, Ca2+ acts as a signalling molecule in acinar cells that has a critical role 
in controlling secretion of digestive enzymes. Prolonged elevation of intracellular Ca2+ 
(triggered by various stimuli, including oxidative stress) can lead the development of 
pancreatitis, where inappropriate activation and overproduction of digestive enzymes 
can result in pancreatic damage, which triggers an inflammatory response (Tonsi et 
al., 2009; Li et al., 2014; Lankisch et al., 2015).  
It has been shown that the inflammatory response can be stimulated independently of 
trypin activation. New insights indicate that trypsin activation is only associated with 
the development of acute pancreatitis, whereas chronic pancreatitis develops 
independently of this activation. The causal factors of chronic panceatitis are believed 
to be similar to those of acute pancreatitis as it usually evolves from acute pancreatitis. 
The exact underlying mechanisms are however unknown. Although alcohol abuse is 
described as a major cause of chronic pancreatitis, only a small percentage of 
alcoholics develop this condition, therefore suggesting that other factors are involved 
(Yamamoto et al., 2006; Lankisch et al., 2015). In most patients, local inflammation of 
the pancreas can be rectified before becoming severe. Unfortunately, in a small 
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percentage of patients in which the local inflammatory response is not controlled, 
systemic inflammation develops, ultimately leading to multiple organ damage 
(Granger & Remick, 2005; Matull et al., 2006; Tonsi et al., 2009). Prolonged and 
continuous inflammation within the pancreas contributes to the development of chronic 
pancreatitis and irreversible morphological alterations result, in which fibrosis is a 
major characteristic. Damage to β- and α-cells can also lead to pancreatic disorders, 
including diabetes (Bachmann et al.  2011; Steer, 2012; French & Charnely, 2016). 
Sustained activation of the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathway has been reported to be implicated in the development of 
chronic pancreatitis (Raghuwansh et al., 2013). NF-κB is an important transcription 
factor that mediates the orchestration of inflammatory molecules by controlling their 
gene expression (Baeurle & Baichwal, 1995; Wulczyn et al., 1996; Ghosh et al., 1998). 
NF-κB remains inactive in the cytoplasm of resting cells. Incoming signals such as 
oxidative stress and inflammatory cytokines at the cell surface trigger the 
hyperphosphorylation of inhibitory-kappa-B (IκB) proteins, including IκB-alpha (IκBα) 
and B-cell lymphoma 3-encoded (Bcl-3) proteins, allowing the release of NF-κB, where 
it translocates into the nucleus and stimulates gene transcription (Altavilla et al., 2003). 
Studies have demonstrated the role of NF-κB in cerulein-induced pancreatitis, where 
downregulation of NF-κB significantly protected the pancreas against damage by 
reducing various inflammatory cytokines (Gukovsky et al., 1998; Steinle et al., 1999). 
Pancreatitis can also be attributed to oxidative stress, where oxidative stress does not 
only damage the pancreas directly, but also activates NF-κB and stimulates the 
inflammatory cascade (Schreck et al., 1991). Powerful anti-oxidants such as vitamin 
E are known to reduce oxidative stress and consequently lead to NF-κB inhibition 
(Hattori et al., 1995; Altavilla et al., 2001). 
In the context of DOX, acute pancreatitis is a potential side effect induced by this 
chemotherapeutic agent (Saleh & Ali, 2015). However, there are major flaws in the 
cases reporting a link between DOX treatment and the development of pancreatitis. 
Firstly, investigators in these cases did not eliminate the more common causes of 
acute pancreatitis, including gallstones and alcohol abuse. Secondly, in some cases 
DOX was administered in combination with other medications (Badalov et al., 2007). 
Despite this, DOX is listed as one of the drugs that is implicated in causing pancreatitis 
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and further investigations are needed to elucidate the effects of DOX on the 
development of pancreatitis (Trivedi & Pitchumoni, 2005; Kaurich, 2008). 
1.6.2 Diagnosing pancreatitis  
The most commonly used biomarker for the diagnosis of acute pancreatitis is serum 
amylase, however its sensitivity can be influenced by chronic alcoholism and 
hypertriglyceridemia. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) are two 
other inflammatory associated cytokines used to predict acute pancreatitis in patients. 
Serum IL-6 levels can be detected between 12 and 24 hours after a patient is admitted 
to hospital, and peak before CRP levels (Matull et al., 2006). Although IL-6 is sensitive 
enough to be used to detect early acute pancreatitis, its concentration in the serum 
rapidly declines, and thus limits its use in the clinical setting (Pezzilli et al., 1999; Matull 
et al., 2006). Plasma TNF-α levels can also be detected early during acute 
pancreatitis. To support the role of the TNF-α/NF-kB signalling pathway during 
pancreatitis, NF-κB knockout mice demonstrated reduced TNF-α levels, leukocyte 
accumulation, and consequently reduced tissue damage. However, TNF-α has a short 
half-life in the serum which should be taken into account when measuring its serum 
levels (Altavilla et al., 2003).  
1.7 Fibrosis within the pancreas 
As previously described, chronic pancreatitis is characterised by continuous and 
progressive fibrosis in the pancreas, though the exact mechanism underlying fibrosis 
remains unknown (Kozak et al., 2016). Repairing injured tissues is a complex process 
that results in the deposition of extracellular matrix (ECM) proteins by fibroblasts, and 
although deposition of these proteins is usually temporary, repeated tissue injury seen 
in chronic pathologies can lead to fibrosis and, ultimately, organ dysfunction 
(Meneghin & Hogaboam, 2007; Wynnand & Ramalingam, 2012). There are usually 
four overlapping stages of tissue repair, namely haemostasis, inflammation, 
proliferation and remodelling, in which many cells play a role in each phase (Guo & 
DiPietro, 2010). During haemostasis and inflammation, platelets secrete cytokines, 
including platelet-derived growth factor (PDGF) and transforming growth factor-beta1 
(TGF-β1). These cytokines recruit white blood cells (macrophages, neutrophils and 
natural-killer cells) to the injured site which remove debris and dead cells, while 
simultaneously releasing more cytokines that simulate fibroblast activation and 
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proliferation, leading to ECM protein production (Koh & DiPietro, 2011). Macrophages 
release TGF-β1, TNF-α and interleukin 1-beta (IL-1β) cytokines which promote 
differentiation and proliferation of fibroblasts into active fibroblasts, and supresses the 
production of key degradative enzymes of ECM proteins, such as matrix 
metalloproteinases (MMPs), ultimately leading to the replacement of damaged cells 
by fibrotic tissue (Petrov et al., 2002; Hall et al., 2003; Wynnand & Ramalingam, 2012; 
Midgley et al., 2013). 
Tissue injury and inflammation increase ROS generation, and TNF-α can promote the 
accumulation of leukocytes within the pancreatic tissue, causing further inflammation 
and organ injury (Altavilla et al., 2003; Shroff, Mamalis and Jagdeo, 2014). As 
inflammation and oxidative stress cannot be easily separated, increased ROS 
production has also been implicated to have a role in pancreatic parenchyma 
destruction, leading to fibrosis (Angelino et al., 2015; French & Charnely, 2016). Under 
stress conditions, over-activity of hepatic detoxification enzymes generate ROS in bile, 
which can undergo reflux up the pancreatic duct, and damage the pancreatic tissue. 
In addition, repeated cycles of inflammation and necrosis can result in necrosis-
induced fibrosis (French & Charnely, 2016).  
Stellate cells in the liver play a critical role in fibrogenesis and are the main producers 
of collagen as well as other ECM proteins. Similar cells have been identified in the 
pancreas, termed pancreatic stellate cells (Haber et al., 1999). In a healthy pancreas, 
these cells are described as having characteristic intracellular lipid droplets, and are 
located in the peri-acinar spaces with long cytoplasmic extensions that encircle the 
base of pancreatic acini. Quiescent, pancreatic stellate cells stain positively for 
desmin, an intermediate cytoskeletal filament protein, and active pancreatic stellate 
cells stain positively for alpha-smooth muscle actin (α-SMA), a cytoskeletal protein 
(Haber et al., 1999; Kishi et al., 2003). While the mechanisms involved in pancreatic 
fibrosis remain to be elucidated, both human and experimental studies demonstrate 
that persistent activation of pancreatic stellate cells is involved in chronic pancreatitis 
development, where these cells are the major source of collagen (Kozak et al., 2016). 
Moreover, the degree of  lymphocyte infiltration correlates with the severity of pain 
experienced by patients (French & Charnely, 2016). Activated pancreatic stellate cells 
are responsive to pro-fibrotic cytokines PDGF and TGF-β1, where in response to 
PDGF, pancreatic stellate cells increase proliferation, and in response to TGFβ1, 
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these cells increase collagen synthesis, contributing to fibrosis (Kishi et al., 2003; 
Haber et al., 1999). In an in vivo model of pancreatic duct ligation-induced fibrosis α-
SMA and collagen Type I expression was weak on day 7 with very little fibrosis visible. 
On the tenth day, α-SMA expression was elevated and fibrosis was shown to be 
significantly increased, illustrating the relationship between pancreatic stellate cell 
activation and fibrosis induction. Since α-SMA and collagen Type I were modestly 
expressed prior to fibrosis, this implies that pancreatic stellate cell activation precedes 
fibrogenesis. With regards to the fate of quiescent pancreatic stellate cells after 
ligation, desmin-positive pancreatic stellate cells still existed and somewhat increased 
in the interlobular areas even on the tenth day following ligation when pancreatic 
stellate cells had already been activated and fibrosis was evident (Kishi et al., 2003).    
1.8 Toxicity of Doxorubicin is not limited to the heart 
As mentioned previously, DOX is an effective and potent anti-cancer drug, however, 
it is associated with severe side effects. While literature has mainly focused on the 
damaging effects induced by DOX on the heart, very few studies have investigated 
DOX’s effect on pancreatic function. Rodent studies have indicated a strong 
correlation between DOX and elevated blood glucose and triglyceride levels, as well 
as dysregulation of adipocyte and muscle metabolism (Arunachalam et al., 2013; 
Biondo et al., 2016; De Lima Junior et al., 2016). While chemotherapeutic drugs have 
been suggested to lead to the development of diabetes in patients, the direct link 
between DOX and diabetes in the clinical setting is yet to be determined (Feng et al., 
2013). Glucose-stimulated insulin secretion is a hallmark of β-cell function and in vitro 
studies previously showed that DOX inhibited glucose-stimulated insulin secretion in 
rat β-cells (DeLeers & Goormaghtigh, 1985; Dispenzieri & Loprinzi, 1997; Geetha et 
al., 1999), although the mechanisms involved remain to be elucidated. In addition, 
DOX was shown to induce apoptosis in isolated β-cells by increasing pro-apoptotic 
Bax and decreasing anti-apoptotic Bcl-2, resulting in increased cytochrome c release 
and caspase-3 activation (Zhang et al., 2007). Recently Heart et al. (2016) 
demonstrated that DOX was highly toxic to isolated murine islets and β-cells, even at 
doses less than that which is administered to patients. This study further elucidated 
that DOX damaged DNA, causing upregulation of p53 and ultimately activation of 
caspase-3. Although the use of caspase inhibitor, Z-VAD-FMK, protected the β-cells 
temporarily at a range of DOX doses, it was unable to prevent the loss of cell viability. 
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DOX may cause similar damage to streptozotocin, a well-known toxin of β-cells, where 
damage to these cell membranes causes insulin release and subsequent cell death. 
Based on the above, it is clear that more research is required to elucidate the exact 
mechanisms involved in DOX toxicity within the pancreas in order to not only assess 
the risk of patients undergoing treatment, but also to find and develop protective 
agents against potential DOX-induced pancreatic damage. 
1.9 Protective agents used against Doxorubicin-induced damage 
As DOX toxicity is associated with elevated oxidative stress, many studies have 
concentrated on reducing oxidative stress in an effort to reduce the consequent 
damage. The first anti-oxidant that was reported to reduce DOX-induced oxidative 
stress was alpha-tocopherol (Vitamin E). While vitamin E reduced oxidative stress, it 
was unable to prevent mitochondrial dysfunction caused by chronic DOX treatment 
(Berthiaume et al., 2005). Vitamin E administered in combination with DOX prevented 
damage to visceral organs, including the heart, liver, testes and kidneys (Shivakumar 
et al., 2012). Synthetic aminothiol (N-(2-mercaptopropionyl glycine) has been shown 
to exhibit anti-oxidative properties that may prevent acute cardiotoxicity in rats (El-
Missiry et al., 2001), and amlodipine, a Ca2+ channel antagonist with potent anti-
oxidant activity, was shown to inhibit DOX-induced apoptosis in cardiomyocytes 
(Yamanaka et al., 2003). Despite these powerful anti-oxidants, very little evidence 
exists to support the notion that anti-oxidants and other anti-oxidant like synthetic 
drugs are able to fully prevent DOX’s off-target toxicity.  
Since DOX can react with free Fe to generate free radicals, the ability of Fe-chelators 
to remove excess free Fe has been investigated. Currently Dexrazoxane (DXZ) is the 
only Fe-chelator used in clinical studies as it has been shown to reduce DOX-induced 
toxicity (Imondi et al., 1996; Swain et al., 1997), by preventing the formation of DOX-
Fe complexes and subsequent OH● generation (Hasinoff et al., 1997). In addition, DXZ 
has been identified as a significant anti-cancer drug where it inhibits the DNA enzyme, 
topoisomerase II, similarly to DOX’s anti-cancer mechanism (Tetef et al., 2001). 
However, it has been reported that DXZ treatment results in secondary malignancies 
in cancer survivors, therefore decreasing the efficacy of DOX (Tebbi et al., 2007).  
Polyphenols found in plants are rich sources of anti-oxidants and are known to 
decrease damage caused by ROS (Habauzit & Morand, 2012). Studies have shown 
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that the use of polyphenols, specifically flavonoids, in combination with DOX 
treatment, prevents DOX-induced toxicity. These effects are attributed to their anti-
cancer and cardioprotective properties (Chung et al., 2010; Huang, 2013). Flavonoids 
are believed to be both Fe-chelators and free radical scavengers. One of the most 
studied plant derived flavonoid is Quercetin, which is a potent flavonoid found in fruit 
and vegetables (Hertog et al., 1993; Bravo, 1998; Jacobs et al., 2010). It is known to 
have anti-inflammatory, anti-oxidant and cardioprotective properties, and has been 
reported to decrease lipid peroxidation when used in combination with DOX treatment 
(Matouk et al., 2013). 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) is a semi-
synthetic flavonoid. Its structure is similar to Quercetin’s chemical structure, and in 
vivo studies have demonstrated its cardioprotective activities during chronic DOX 
treatment (Van Acker et al., 1995, Van Acker et al., 1997). Unfortunately, monoHER 
has negative effects on the cardiac glutathione system and, thus, its use in the clinical 
setting has failed to reproduce the same protective effects (Bruynzeel et al., 2007). 
Due to the disappointing results obtained in clinical trials utilising anti-oxidants as an 
intervention to protect against DOX toxicity, targeting only oxidative stress in a 
condition that is multi-faceted will not suffice. This fact, therefore, indicates that more 
investigations are required to find effective therapies that act in ways other than what 
is currently established.   
1.10 Ghrelin 
1.10.1 Structure of ghrelin 
Ghrelin is a 28-amino acid peptide that was originally isolated from both the rat and 
human stomach as an endogenous ligand for the growth hormone secretagogue 
receptor type 1-apha (GHS-R-1α) (Kojima et al., 1999; Tomasetto et al., 2000). Ghrelin 
is generated by the processing of preproghrelin, where the serine residue in the third 
position of desacyl ghrelin is octanoylated to form bioactive acylated ghrelin. The 
acetylated form acts as a ligand for the GHS-R-1α and throughout this study will 
merely be referred to as ghrelin. The unique modification at serine position 3 (serine-
3) by a fatty acid, primarily n-octanoinc acid, permits its effects on the GHS-R-1α 
(Figure 1.8). Ghrelin is secreted in response to the nutritional status of the body, where 
during fasting, circulating ghrelin levels are high, and during feeding, ghrelin levels are 
low (Kageyama et al., 2005; Kojima & Kangawa, 2005; Qader et al., 2008). The 
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circulating ghrelin is mainly produced by the X/A-like cells of the oxyntic gastric 
mucosa and small intestine (Date et al., 2000). A small amount of ghrelin has been 
shown to be produced in other organs of the body, including the pancreas (Leite-
Moreira & Soares, 2007). 
 
 
 
 
 
 
 
 
 
Figure 1.8: Structure of human and rat ghrelin molecules. Both human and rat 
ghrelin is 28-amino acid in length, where the unique modification of serine-3 by a fatty 
acid, mainly n-octanoic acid, allows it to bind to its receptor GHS-R-1α. Adapted from 
Kojima & Kangawa (2005). 
Ghrelin cells, also termed epsilon-cells (ε-cells), are located in the pancreatic islets. In 
humans, these cells have been shown to be numerous in foetal and neonatal islets, 
and are observed in the islet periphery, while in the adult islets only a few ε-cells are 
visible (Wierup et al., 2002). Furthermore, ε-cells comprise of approximately 10% of 
all islets in both foetal (15 - 26 weeks of gestation) and neonatal islets, while only 
approximately 1% are present in adult islets (Wierup et al., 2014). Interestingly, in both 
humans and rodents, when comparing the foetal pancreas and the foetal stomach, the 
pancreas was found to possess more ε-cells, while very few X/A cells were found in 
the stomach, suggesting an inverse correlation between ε-cell and gastric X/A cell 
density (Wierup et al., 2002; Wierup et al., 2014). The density of ε-cells peaks at birth, 
while 40 days after birth (approximately six weeks old) these cells are occasionally 
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visible, and in adult islets they are rarely seen. Thus, the pancreas is suggested to be 
the main source of ghrelin during foetal development (Fak et al., 2007; Walia et al., 
2009). 
Studies have reported that ghrelin receptors are not only expressed in the central 
nervous system, particularly in the anterior pituitary and hypothalamus, but are also 
expressed in peripheral tissues, including the pancreatic islets, suggesting ghrelin has 
other effects within the body (Date et al., 2002; Kageyama et al., 2005; Işeri et al., 
2008; Chopin et al., 2011). Ghrelin stimulates GH release by binding to GHS-R-1α in 
the pituitary gland, which causes an increase in intracellular Ca2+ and results in GH 
secretion (Date et al., 2002). However, in addition to its effects on GH secretion, 
ghrelin has a wide variety of critical functions within the body as demonstrated in 
Figure 1.9 (Tschöp et al., 2000; Wren et al., 2001; Choi et al., 2003; Zhang et al., 2007; 
Delporte, 2013). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: The main physiological effects of ghrelin within the body. Ghrelin has a wide 
variety of critical functions in the body, affecting several vital organs. Abbreviations: GH 
(growth hormone), ↑ (increases), ↓ (decreases). 
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1.10.2 The interactions between ghrelin and the pancreatic hormones 
Whether ghrelin is involved in regulating hormonal secretion from the pancreas 
remains controversial. While some studies indicate that ghrelin inhibits insulin 
secretion in clonal β-cells, rodents and humans (Broglio et al., 2001; Egido et al., 2002; 
Kvist Reimer et al., 2003), other studies indicate that ghrelin does in fact stimulate 
insulin secretion (Date et al., 2002; Lee et al., 2002; Cummings et al., 2005). It is 
thought that these discrepancies may reflect differences in species and experimental 
design, such as doses administered and time of observation. Furthermore, both 
plasma ghrelin and insulin levels are glucose-dependant, in which high plasma 
glucose levels stimulate insulin secretion and suppress ghrelin secretion, indicating 
that plasma glucose is another important factor to consider in these studies (Kojima & 
Kangawa, 2005). Alternatively, insulin is suggested to inhibit ghrelin secretion, where 
an inverse correlation between ghrelin and insulin plasma levels exists (Korbonits et 
al., 2004; Dezaki et al., 2008). This inhibitory effect of insulin may explain the 
suppression of ghrelin secretion induced by high plasma glucose levels, and suggests 
that ghrelin’s stimulatory effect on insulin secretion shown in some studies seems 
unlikely (Yin et al., 2009; Wierup et al., 2014). From a physiological perspective, this 
makes sense as plasma glucose levels are high after feeding, stimulating insulin 
secretion, both of which suppress ghrelin secretion. The opposite occurs during the 
fasted state when plasma glucose levels no longer stimulate insulin secretion, thus, 
the inhibition on ghrelin secretion is lifted (Tschöp et al., 2000; Dornonville de la Cour 
et al., 2001; Toshinai et al., 2001). Regarding the effects of ghrelin on glucagon, 
somatostatin, and PP secretion, a study using perfused rat pancreas reported ghrelin 
had no effect on glucagon secretion, but inhibited somatostatin secretion (Egido et al., 
2002). In contrast, other studies have shown that ghrelin stimulated glucagon 
secretion in isolated islets, although this effect was not reflected in intact mice (Salehi 
et al., 2004). Similarly in humans, ghrelin has been reported to stimulate somatostatin 
and PP secretion (Arosio et al., 2003). Evaluating glucagon’s effect on ghrelin 
secretion, it is suggested that glucagon stimulates ghrelin secretion as plasma 
glucagon levels increase during the fasted state (Yin et al., 2009). In support of the 
above, Katayama et al. (2007) demonstrated that the exogenous administration of 
glucagon to experimental animals promotes ghrelin secretion. However, in contrast, 
the intramuscular injection of glucagon in humans reduces plasma ghrelin levels 
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potentially via the hypothalamic-pituitary axis (Arafat et al., 2005, Arafat et al., 2006). 
While additional research is necessary to understand the relationship between these 
hormones and their effects on one another, the beneficial effects of ghrelin should also 
be explored.  
1.10.3 The protective effects of ghrelin during Doxorubicin treatment  
Cachexia, or involuntary weight loss, is well-known to develop in cancer patients, and 
DOX has been associated with muscle atrophy and fat loss (De Lima Junior et al., 
2016), thus, ghrelin’s appetite stimulating and adipogenesis effects in this context 
could be beneficial. A rodent study reported that during cachexia, ghrelin 
administration increased food intake, lean muscle mass and fat mass (Strassburg et 
al., 2008), suggesting this to be a possible treatment therapy that could lead to 
improvements in the quality of life of patients undergoing chemotherapy. In addition, 
ghrelin has also been shown to have anti-oxidative, anti-inflammatory, anti-apoptotic 
and anti-fibrotic activities, which have been demonstrated in a variety of cells and 
tissues (Tong et al., 2012; Yang et al., 2013; Barazzoni et al., 2014; Dobutovic et al., 
2014). Ghrelin has been shown to prevent DOX-induced apoptosis by reducing 
oxidative stress, ultimately leading to reduced fibrosis (Dixit et al., 2004; Pei et al., 
2014; Wang et al., 2014). Moreover, studies investigating the effects of ghrelin in 
fibrotic diseases showed that ghrelin reduces pro-inflammatory cytokine expression, 
including IL-6, IL-1β and TNF-α, and prevents macrophage infiltration, resulting in 
reduced collagen Type I, collagen Type II, fibronectin and α-SMA expression (Huang 
et al., 2009; Li et al., 2013; Sun et al., 2015). However, while ghrelin’s protective effects 
are demonstrated in several organs of the body, literature is lacking regarding its 
effects on the pancreas.     
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1.11 Problem statement  
DOX is a potent chemotherapeutic agent that is used to treat a variety of different 
cancers and has contributed to the improved survival of patients. However, although 
effective, chronic DOX treatment is associated with off-target toxicity, particularly in 
cardiomyocytes. While literature has focused mainly on investigating the mechanisms 
involved in DOX-induced toxicity in the heart and other organs of the body, there are 
limited studies regarding the pancreas. Moreover, it is imperative that a therapeutic 
strategy is established that not only prevents DOX-induced toxicity, but also does not 
interfere with its anti-cancer effects in order to prolong survival of these cancer 
patients. Though anti-oxidants have been used in the clinical setting to reduce DOX-
induced oxidative stress, they have yielded disappointing results. This brings us to 
ghrelin, a brain-gut peptide more commonly known for its appetite-inducing and GH-
releasing effects. Ghrelin has been reported to exhibit beneficial properties in a variety 
of cells and tissues, including anti-oxidative, anti-apoptotic, anti-inflammatory and anti-
fibrotic activities. However, studies are lacking with regards to investigating the 
protective effects of ghrelin in the pancreas.  
1.12 Hypothesis and research aims 
Although cells in the body have different functions, they all have similar cellular 
organelles that can be damaged by DOX treatment. Since oxidative stress and 
apoptotic cell death are believed to be the two major contributors to DOX-induced 
toxicity, this study hypothesised that DOX induces oxidative and apoptotic damage in 
pancreatic cells that will lead to the development of pancreatitis and fibrosis in the long 
term. In addition, ghrelin’s protective effects against DOX-induced damage have been 
demonstrated in various organs, therefore, this study hypothesised that ghrelin will 
exhibit similar protective effects in the pancreas. 
This study aimed to: 
1. Investigate the effects of DOX treatment on the pancreas in a chronic model of 
DOX-induced toxicity by evaluating oxidative stress, apoptosis, inflammation and 
fibrosis. 
2. Assess the potential of ghrelin to ameliorate these effects through its proposed 
anti-oxidant, anti-apoptotic, anti-fibrotic and anti-inflammatory effects.  
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CHAPTER 2: Materials & Methods 
2.1 Ethical approval and animal care 
Animals used in this study were treated adhering to the accepted standards for the 
use of animals in research and teaching as reflected in the South African National 
Standards 10386: 2008, and conformed to the guidelines for the care and use of 
laboratory animals implemented at Stellenbosch University. Approval for this study 
was obtained by the Animal Ethics Committees of Stellenbosch University (South 
Africa), (Ethics # SU- ACUD15-00038) (Appendix A). 
Male Sprague Dawley rats (n = 32) were obtained at four weeks old and were allowed 
one week to acclimatize to the animal facility before the study commenced. As this 
study aimed to assess the effects of DOX on the pancreas using a model of chronic 
cardiotoxicity, often observed in survivors of childhood cancers, the age of the animals 
at the start of treatment were of equivalent age to late childhood in humans and early 
adulthood by the end of treatment. The rats were housed at 25 °C in sterile ventilated 
cages on a 12-hour light/dark cycle. Standard rat chow and tap water were provided 
ad libitum.  
2.2 Experimental procedure 
At five weeks, animals were randomly divided into vehicle (n = 7), ghrelin (n = 7), DOX 
(n = 9) and DOX+ghrelin (n = 9) treatment groups. The vehicle group was treated with 
200 μl of physiological saline, the Ghrelin group received 100 µg/kg of ghrelin (G2869, 
LKT Laboratories, Inc., Minnesota, USA) three times a week, the DOX group received 
2.5 mg/kg of DOX (D5794, LKT Laboratories, Inc., Minnesota, USA) once a week and 
the combination group received both treatments, respectively. All treatments were 
conducted via intraperitoneal injection using 25-gauge needle (HLSCDN-25, Lasec, 
Cape Town, South Africa) over a period of eight weeks. The cumulative dose of DOX 
for the duration of the study was thus 20 mg/kg, which, when translated to human 
doses, is clinically relevant. As DOX is a known cytotoxic agent, and very little is known 
about the adverse effects of ghrelin in this context, if any, animals were constantly 
monitored, weighed and food consumption recorded. No animals were lost as a result 
of the treatment (Appendix B). 
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2.3 Serum and tissue collection  
A week after the last injection, animals were anaesthetised with a lethal dose (60 
mg/kg) of sodium pentobarbitone (Euthapent, 130540, Kyron Laboratories, 
Johannesburg, South Africa). When the pedal reflex was no longer observed, a 
recognition and confirmation of death (Close et al., 1996), the abdominal cavity was 
cut open and the pancreas was harvested from each animal. After weighing each 
pancreas, the organ was non-specifically divided into two sections, where one half 
was preserved in a 4% formaldehyde solution (100496, Merck Millipore, 
Massachusetts, USA) for histological analysis, and the other half was snap frozen in 
liquid nitrogen and stored at – 80 °C in for biochemical analysis.  
At the time of euthanasia, blood was also collected from the thoracic cavity of each 
animal using a 10 ml sterile syringe upon removal of the heart. The blood was 
immediately placed into serum separation tubes (VGRV450470R, Lasec, Cape Town, 
South Africa), where after the tubes were inverted five times and placed on ice for 10 
minutes to stand. The tubes were then centrifuged for 10 minutes at 4 000 rpm (1 400 
x g) at 4 °C and the supernatant aliquoted into centrifuge tubes and stored at - 80 °C 
(Appendix C).  
2.4 Metabolic parameters assessed in serum  
MILLIPLEX® MAP Multiplex assay was used to analyse serum samples. The serum 
concentrations of glucagon, insulin, IL-6 and TNF-α were measured using a rat 
metabolic magnetic kit (RMHMAG-84K, Merck Millipore, Massachusetts, USA). 
Luminex xMAP® technology is based on beads (or microspheres) that are covalently 
coupled with a specific capture antibody and is used to detect multiple analytes from 
a single sample of a small volume. Each bead is distinctly coloured internally using 
two fluorescent dyes at discrete ratios. After cytokines in the serum bind to the anti-
bodies on the beads, a biotinylated detection antibody is added and streptavidin-
phycoerythrin conjugate, the fluorescently labelled reporter molecule, is added to 
complete the reaction (Houser, 2012). The Bio-Plex® MAGPIX™ Multiplex reader 
(MAGPIX13046704, BioRad, Johannesburg, South Africa) was then used to identify 
each bead and the fluorescent signal quantified using MAGPIX® with xPONENT® 
software. The assay was carried out as per the manufacturer’s instructions. 
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In brief, a black 96-well plate was prewashed with Assay Buffer and serum matrix 
solution, where after the assay buffer, standards, quality controls, bead solution and 
samples were loaded into appropriate wells. The plate was sealed and incubated 
overnight (18 - 20 hours) with slight agitation at 4 °C to allow for binding of serum 
proteins to anti-bodies on the beads. This was followed by aspiration and washing 
steps using a Bio-Plex Pro™ Wash Station (BioRad, Johannesburg, South Africa). 
The plate was then incubated at room temperature with slight agitation firstly with the 
prepared Detection Antibodies, and then Streptavidin-Phycoerythrin was loaded into 
each well and the plate was incubated further. The solution in the wells were aspirated 
and washed as previously described, and incubated with MAGPIX® Drive Fluid (40-
50013, Luminex) with slight agitation to resuspend the beads (Appendix D).  
2.5 Histological analysis 
2.5.1 Tissue processing and sectioning  
The fixed pancreatic tissue samples were removed from the 4% formaldehyde solution 
and transferred onto labelled cassettes (Z672122, Sigma-Aldrich, St Louis, USA). The 
tissues were processed through a series of dehydration steps using a TissueTek® II 
automated tissue processing machine (4640B, Lab-Tek division, Miles Laboratories 
Inc, Naperville, Illinois, USA), and infiltrated with Paraplast® wax (A6330-4LB, Sigma-
Aldrich, St Louis, USA) (Appendix E). After processing, tissues were embedding with 
melted paraffin wax (8002-74-2, Merck Millipore, Massachusetts, USA) onto a cassette 
(PLPS191023, Lasec, Cape Town, South Africa) using the Leica Modular Tissue 
Embedding Centre (EG1160, Lecia Biosystems, Wetzlar, Germany). Using a manual 
microtome (RM 2125 RT, Leica Biosystems, Wetzlar, Germany), 5 µm thick sections 
were prepared, carefully transferred onto appropriate microscope slides, and placed 
briefly into a 60 °C oven to ensure adhesion and drying of the sections. 
2.5.2 Haematoxylin and eosin (H&E) staining  
In histology, the H&E stain is the most widely used stain due to its ability to clearly 
display different structures of the tissue. Haematoxylin stains nuclei black by binding 
to the anionic DNA and RNA, while eosin stains the cytoplasm components in various 
shades pink due to its high affinity for positively charged cytoplasmic constituents 
(Bancroft & Gamble, 2008). A Leica Auto Stainer XL (ST5010, Leica Biosystems, 
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Wetzlar, Germany) was used for the H&E staining. The Mayer’s Haematoxylin solution 
(SAAR2822001LC, Merck Millipore, Massachusetts, USA) was filtered and the Eosin 
solution (3801600E, Leica Biosystems, Wetzlar, Germany) was freshly prepared prior 
to sectioning. The 5 μm sections previously prepared were stained and the microscope 
slides (GLAS4S22M3000F, Lasec, Cape Town, South Africa) were mounted with 
coverslips (GLAS2C9M2250REC, Lasec, Cape Town, South Africa) using DPX 
mountant (06522, Sigma-Aldrich, St Louis, USA) and allowed to dry overnight 
(Appendix F). 
Images were acquired with a 40 X objective lens on a E400 ECLIPSE microscope 
(Nikon Instruments, Japan) using a DS-Fi2 camera (Nikon Instruments, Japan) with 
NIS Elements version 4.10 software (Nikon, Japan), on a Dell desktop computer (Dell, 
United States of America) running Microsoft Windows 7 software (Microsoft, United 
States of America).  
2.5.3 Masson’s Trichrome staining  
Masson’s Trichrome stain is used in histology to stain collagenous connective tissue 
and, as its names implies, employs three dyes. The Masson Trichrome protocol used 
in this study was described by (Bancroft & Gamble, 2008), where collagen is stained 
green, cytoplasm is stained red while the nuclei are stained black. 5 μm sections were 
prepared as described previously and were transferred onto positively charged 
Histobond microscope slides (GLAS2S13M0810401, Lasec, Cape Town, South 
Africa). Following staining, the slides were mounted and allowed to dry. Sections of 
skin were used as positive control slides (Appendix G).   
Images were obtained using the same microscope and software as indicated in section 
2.5.2., and images were acquired at 4 X magnification. 20 images of random areas of 
the pancreas were captured for each treatment group. Images were brightened to 
make each colour stand out for easier differentiation and analysed using ImageJ 
software (Schneider et al., 2012). The images were analysed as described by Bauman 
et al., 2014 with modifications. Blue-green coloration, indicative of fibrosis, was 
separated by manual thresholding of hue (60 - 190), saturation (35 - 255), and 
brightness (10 - 255) values using ImageJ software. The value, or pixels, of the 
interstitial fibrotic areas (blue area) were represented as the percentage of the entire 
tissue (red area) analysed. This is illustrated by the equation below: 
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% 𝐹𝑖𝑏𝑟𝑜𝑡𝑖𝑐 𝑎𝑟𝑒𝑎 =  
𝐵𝑙𝑢𝑒 𝐴𝑟𝑒𝑎𝑠 (𝐹𝑖𝑏𝑟𝑜𝑡𝑖𝑐 𝐴𝑟𝑒𝑎𝑠)
𝑅𝑒𝑑 𝐴𝑟𝑒𝑎 (𝐸𝑛𝑡𝑖𝑟𝑒 𝑇𝑖𝑠𝑠𝑢𝑒)
 × 100 
2.5.4 Immunohistochemical staining 
In order to compare any significant changes observed in the serum glucagon and 
insulin levels of the animals between treatment groups, this study assessed the 
percentage of α- and β-cells within the islets of Langerhans. 5 μm sections were 
prepared as previously described. Positively charged Histobond microscope slides 
were again used for this stain where sections were deparaffinised, and rehydrated 
through a graded series of ethanol and stained using a Leica Bond-Max™ Immuno-
Autostainer (ST5010, Lecia Biosystems, Wetzlar, Germany). Sequential double-
staining was utilised for glucagon (ab10988, Abcam, Cambridge, United Kingdom) and 
insulin (ab7842, Abcam, Cambridge, United Kingdom) antibodies, using a Bond™ 
Polymer Refine Detection Kit (DS9800, Leica Biosystems, Wetzlar, Germany) and a 
Bond™ Polymer Refine Red Detection Kit (DS9390, Leica Biosystems, Wetzlar, 
Germany). In brief, sections were pre-treated with epitope-retrieval reagent in order to 
re-open the cross-linked and covered epitopes that occurred during fixation. 
Endogenous peroxidases were blocked using H2O2 in order to prevent background 
staining and to avoid obtaining false positives staining (Chen et al., 2010). The Bond™ 
Polymer Refine Detection Kit is a horseradish peroxidase (HRP)-linked conjugate 
system, which converts the 3,3’-diaminobenzidine tetrahydrochloride hydrate (DAB) 
chromogen into a brown precipitate, while the Bond™ Polymer Refine Red Detection 
Kit is an alkaline phosphatase (AP)-linked conjugate system, which converts 3-amino-
9-ethylcarbazole (AEC) into a red precipitate. This allows for the detection of tissue-
bound Immunoglobulin G (IgG) primary antibodies and easy antigen differentiation. 
Both kits contain haematoxylin counterstains in order to visualise nuclei. Glucagon-
secreting α-cells were stained brown, and insulin-secreting β-cells were stained red. 
After staining, tissues were mounted on slides, and cover slipped and allowed to dry 
(Appendix H).  
Images were obtained using the same microscope and software as indicated in section 
2.5.2. Twenty islets of Langerhans from each treatment group were randomly 
selected, and the number of α-cells and β-cells were manually counted using ImageJ 
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software. These results were presented as a percentage of α-cells and β-cells present 
in one islet per treatment group. 
2.6 Oxidative stress analysis 
DOX-induced oxidative stress suggested to be one of the main mechanisms by which 
DOX induces cell damage (Mizutani et al., 2003), and are neutralised by endogenous 
enzymatic anti-oxidant systems. This study, therefore, employed the oxygen radical 
absorbance capacity (ORAC) assay that is indicative of the ‘anti-oxidant power’, SOD 
activity and glutathione (GSH: GSSG) assays to determine the influence of DOX and 
oxidative stress on the activity of these anti-oxidants. Furthermore, oxidative damage 
was measured by assessing the concentrations of conjugated dienes (CDs) and 
malondialdehyde (MDA), which are early and late markers of lipid peroxidation, 
respectively, using CDs and Thiobarbituric acid reactive substances (TBARS) assays. 
2.6.1 Sample preparation  
100 mg frozen pancreatic tissue samples were crushed using a chilled mortar and 
pestle and placed into chilled centrifuge tubes. For the ORAC, SOD, GSH, CDs and 
TBARS assays, tissues were incubated in 1 ml of cold 50 mM phosphate buffer (pH 
7.5), whereas for the GSSG assay, 10 μl of 1-methyl-2-vinylpyridinium (M2VP) (69701, 
Sigma-Aldrich, St Louis, USA) was added in addition to the phosphate buffer. Tissues 
were homogenised on ice for approximately ten seconds using a POLYTRON™ PT 
2100 benchtop homogeniser (Kinematica AG, Luzern, Switzerland) and the 
centrifuged for ten minutes at 12 000 rpm (13 300 x g). The supernatant was 
transferred into new chilled centrifuge tubes and frozen at – 80 °C until required 
(Appendix I). On the day the assays were performed, samples were thawed on ice 
and centrifuged at 14 000 rpm (16 000 x g) for ten minutes at 4 °C. 
2.6.2 Assessment of the antioxidant capacity 
The ORAC assay is the most widely used assay to determine the antioxidant status of 
samples, and is based on the ability of hydrophilic antioxidants in a sample to prevent 
peroxyl-radical-induced oxidation. Thus, the limitation of this assay, however, is its 
inability to measure hydrophilic antioxidants in the sample, including glutathione (Prior 
et al., 2003). This assay, previously described by Ou et al., 2001, employs fluorescent 
probe Fluorescein (F6377, Sigma-Aldrich, St Louis, USA) as the target, which 
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becomes oxidised after the addition of the peroxyl radical 2,2’-azobis (2-
methylproprionamidine) dihydrochloride (AAPH, 440914, Sigma-Aldrich, St Louis, 
USA). Anti-oxidants present in the samples prevent the oxidation and subsequent 
fluorescent decay of Fluorescein until anti-oxidant activity is depleted. This activity is 
quantified over time by measuring the area under the curve (AUC). Trolox™ (238813, 
Sigma-Aldrich, St Louis, USA), a hydrophilic analog of vitamin E, is used as the 
reference antioxidant in this experiment, where the anti-oxidant capacity of each 
sample is represented as Trolox equivalents (μmol) per gram of tissue analysed.   
The Fluoroskan Ascent™ Microplate Fluorometer (5210470, Thermo Fishcher 
Scientific, Massachusetts, USA) was set at 37 °C.  Samples were prepared as 
previously described in 2.7.1., thawed on ice and centrifuged at 14 000 rpm (16 000 x 
g) for ten minutes to remove turbidity. 100 µl of 0.5 M Perchloric acid (PCA, 100514, 
Merck Millipore, Massachusetts, USA) was added to every 100 µl of sample into a new 
Eppendorf tube to precipitate the protein as the protein fraction in the sample is able 
to significantly mask and interfere with accurate anti-oxidant capacity measurements 
(Prior et al., 2003). Standards and samples were loaded into appropriate wells of a 
black 96-well plate, and Fluorescein and AAPH were loaded into all wells. The 
fluorescence of the fluorescein molecule (excitation: 485 nm, emission: 538 nm) was 
measured every five minutes for two hours. The final ORAC values were calculated 
using the regression equation y = 𝑎𝑥2 + 𝑏𝑥 = 𝑐 between the Trolox concentration (μM) 
and the area under the curve (Appendix J).   
2.6.3 Determination of the antioxidant status 
2.6.3.1 SOD activity assay 
The SOD enzyme is considered to be the first line of defence against ROS in cells 
(Houmani et al., 2016), and this assay was thus employed in this study. The principle 
of the SOD assay is based under physiological conditions where 6-hydroxydopamine 
(6-HD) rapidly auto-oxidises and contributes to an increase in absorbance at 490 nm 
(Heikkila and Cabbat, 1976). Since SOD inhibits this auto-oxidation by consuming the 
O2●− produced, the activity of SOD can be measured by monitoring the auto-oxidation 
of 6-HD. 
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Samples were prepared as described previously in 2.7.1., thawed on ice and 
centrifuged at 14 000 rpm (16 000 x g) for ten minutes. Protein concentration was 
determined using the Direct DetectTM Infrared Spectrometer (DDHW00010-WW, 
Merck Millipore, Massachusetts, USA). This system determines protein concentration 
by measuring the absorbance of amide bonds in protein chains using infrared 
quantification. In brief, 2 µl of blank (SOD assay buffer) and samples were pipetted 
onto the transparent hydrophilic polytetrafluoroethylene (PTFE) membranes of the 
Direct Detect® Assay-free Cards (DDAC00010-GR, Merck Millipore, Massachusetts, 
USA) and placed into the Direct Detect® Infrared Spectrometer, where protein 
concentration was measured as mg/ml of protein. 6-HD (162957, Sigma-Aldrich, St 
Louis, USA) was prepared by dissolving it in PCA and loaded into all wells of a clear 
96-well plate. The blank and samples were loaded into appropriate wells, after which 
diethylenetriaminepentaacetic acid (DETAPAC) (D6518, Sigma-Aldrich, St Louis, 
USA) was loaded into all wells and the plate was immediately place into plate reader. 
The absorbance of each sample was measured at 490 nm using the MultiskanTM 
Spectrum microplate spectrophotometer (51119200, Thermo Fisher Scientific, 
Massachusetts, USA) every minute for four minutes. The SOD activity in the samples 
was measured by comparing the values in each well to a linear calibration curve and 
results were expressed as Unit inhibition/mg of protein. One unit of SOD is defined as 
the amount of SOD required to exhibit 50% dismutation of the O2●− (Appendix K).  
2.6.3.2 Glutathione assays 
The anti-oxidant glutathione peroxidase (GPx) removes H2O2 by coupling its reduction 
(GSH) to H2O2 with the oxidation of glutathione (GSSG). Thus, GSH neutralises free 
radicals by donating an electron and forms GSSG. GSSG is recycled back to GSH by 
glutathione reductase (GR), which is NADPH-dependent (Asensi et al., 1999; Noctor 
et al., 2012). In the absence of oxidative stress, a higher GSH concentration with a 
relatively small GSSG concentration is present in cells. The ratio of GSH to GSSG, 
termed the glutathione status, is considered a good indicator of oxidative stress. The 
total glutathione (GSHtotal) and GSSG concentrations in this study were measured 
using the method described by Asensi et al. (1999), in which the GSH concentration 
within the samples was calculated using the equation: GSH = GSHtotal – 2 GSSG. 5 
5'-dithiobis-(2-nitrobenzoic acid) (DTNB, D8130, Sigma-Aldrich, St Louis, USA) has 
the ability to oxidise with GSH in a sample to produce both GSSG and 5-thio-2-
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nitrobenzoic acid (TNB), which gives a yellow colour. This is then used to quantify the 
amount of GSH present in the sample. For the GSSG assay, the M2VP added during 
sample preparation binds to GSH, allowing only the GSSG concentration to be 
measured. 
Samples were prepared as previously described, thawed on ice and centrifuged at 
14 000 rpm (16 000 x g) for ten minutes. Samples for the GSH assay were diluted 0.5 
X in assay buffer. Standards and samples were loaded into appropriate wells of a clear 
96-well plate, and DTNB and GR (G3664, Sigma-Aldrich, St Louis, USA) were loaded 
into all wells, after which NADPH (N7505, Sigma-Aldrich) was added and the plate 
was immediately place into plate reader. The absorbance values of each sample were 
measured at 412 nm every 30 seconds for five minutes using the MultiskanTM 
Spectrum microplate spectrophotometer (51119200, Thermo Fisher Scientific, 
Massachusetts, USA). The results for GSH and GSSG were then determined using the 
GSH standard (Appendix L). 
2.7 Assessment of oxidative damage 
It is well known that lipid peroxidation is involved in the pathogenesis of a variety of 
diseases and clinical conditions, including anthracycline-induced cardiotoxicity, 
inflammation and fibrosis. A variety of organelles contain membranes, such as 
mitochondria and the endoplasmic reticulum, therefore damage to these membranes 
can be detrimental to cell survival and function (Devasagayam et al., 2003). Lipid 
peroxidation occurs when fatty acids present within membranes are oxidised and form 
lipid hydroperoxide (Botsoglou et al., 1994). CDs are one of the initial products 
produced during lipid peroxidation, which can undergo further oxidation to form lipid 
peroxyl radicals, which can react with more membrane lipids and propagate lipid 
peroxidation. Lipid peroxyl radicals are unstable molecules and break down to form 
several products, including aldehydes such as MDA (Situnayake et al., 1990; 
Devasagayam et al., 2003). Therfore, CDs and MDA can be measured as early and 
late markers of lipid peroxidation respectively.  
2.7.1 Conjugated dienes (CDs) assay 
The concentration of CDs present in the pancreas was determined as described by 
Gul et al (Gül et al., 2003). Samples were prepared as previously described, thawed 
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on ice and centrifuged at 14 000 rpm (16 000 x g) for ten minutes. A 2:1 solution of 
chloroform (102444, Merck Millipore, Massachusetts, USA) and methanol (106007, 
Merck Millipore, Massachusetts, USA) was added to each sample, followed by distilled 
water. This solution was vortexed and centrifuged at 12 000 rpm (13 300 x g) at 4 °C 
for ten minutes to separate the different phases. The bottom chloroform layer was 
transferred into new centrifuge tubes. As the chloroform layer contains a purified lipid 
extract (Bligh et al., 1959), it was allowed to evaporate overnight at 4 °C. The following 
day, the remaining residue was reconstituted with cyclohexane (102822, Merck 
Millipore, Massachusetts, USA), vortexed and loaded into a clear 96-well ultra-violet 
(UV) plate for spectrophotometric analysis. The standard and samples were loaded 
into appropriate wells, where after the absorbance of each sample was measured at 
234 nm using the MultiskanTM Spectrum microplate spectrophotometer (51119200, 
Thermo Fisher Scientific, Massachusetts, USA. CDs absorb maximally at 233 nm to 
235 nm in UV light and, thus, this property is used as the basis for CD detection in 
biological samples (Situnayake et al., 1990). The concentration of CDs was calculated 
using the formula below and expressed as µmol CDs /gram of tissue (Appendix M).  
(𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑡 234 𝑛𝑚) − (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑙𝑎𝑛𝑘 𝑎𝑡 234 𝑛𝑚)
𝑒𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 2.95 𝑥 104
 
 
2.7.2 Thiobarbituric acid reactive substances (TBARS) assay  
MDA reacts with two molecules of TBA to form a complex that gives a pink colour, 
which can be colorimetrically quantified to determine the concentration of MDA 
(Botsoglou et al., 1994). Measuring the concentration of MDA is considered the most 
commonly used approach in estimating the amount of lipid peroxidation 
(Devasagayam, Boloor and Ramasarma, 2003). 
Samples were prepared as previously described, thawed on ice and centrifuged at 
14 000 rpm (16 000 x g) for ten minutes. Samples were added to 4 mM Butylated 
hydroxytoluene (BHT, B1378, Sigma-Aldrich, St Louis, USA) in order to prevent 
oxidation during sample processing. 0.2 M Ortho-Phosphoric acid (100573, Merck 
Millipore, Massachusetts, USA) and 0.11 M TBA was also added to assist in breaking 
up the tissues further. The reaction solutions were boiled in a 90 °C waterbath for 45 
Stellenbosch University  https://scholar.sun.ac.za
55 
 
minutes and immediately cooled in an ice bath. Butanol and saturated salt solution 
were added to each sample and centrifuged at 14 000 rpm (16 000 x g) for 20 seconds 
to separate the phases, after which the top butanol phase and blank were transferred 
into appropriate wells of a clear 96-well plate. The absorbance was measured at 532 
nm using the same spectrophotometer described in section 2.7.1. The concentration 
of MDA was determined by using the known extinction coefficient of the MDA-TBA 
complex (1.55 x 105 M/cm) and expressed as µmol/L of MDA (Appendix N). 
2.8 Western blot analysis 
2.8.1 Tissue lysate preparation and protein determination   
Frozen pancreatic tissue samples were crushed using a chilled mortar and pestle. 
Protein was extracted with 300 µl of modified radio-immunoprecipitation (RIPA) buffer 
(pH 7.4) containing 50 mM Tris-HCl, 150 mM NaCl, 1mM Ethylenediaminetetraacetic 
acid (EDTA, EDS, Sigma-Aldrich, St Louis, USA), 1% Nonidet P 40 (NP-40, 74385, 
Sigma-Aldrich, St Louis, USA), 0.25% Na-deoxycholate (D6750, Sigma-Aldrich, St 
Louis, USA). The buffer was supplemented with 1 mM sodium fluoride (NaF, 106449, 
Merck Millipore, Massachusetts, USA), 1 mM sodium orthovanadate (Na3VO4, S6508, 
Sigma-Aldrich, St Louis, USA), 1 mM phenylmethylsulfonyl fluoride (PMSF, 93482, 
Sigma-Aldrich, St Louis, USA) and 1 x cOmplete™ protease inhibitor cocktail 
(11873580001, Roche, Basel, Switzerland) to inhibit phosphatase and protease 
activities. Tissue was homogenised in chilled centrifuge tubes for approximately ten 
seconds using a POLYTRON™ PT 2100 benchtop homogeniser (Kinematica AG, 
Luzern, Switzerland). Once the foam had subsided, lysates were centrifuged twice at 
14 000 rpm (16 000 x g) at 4 °C for an hour and then again for 15 minutes, where the 
supernatant was transferred into new chilled centrifuge tubes after each centrifugation. 
Protein concentration was determined using Direct DetectTM Infrared Spectrometer as 
previously described. 
2.8.2 Sample preparation 
Following protein determination, 56.25 µg protein samples were prepared in Laemmli’s 
sample buffer, boiled at 95 °C for five minutes and stored at - 80 °C until required. 
Prior to loading into polyacrylamide gels, samples were thawed on ice and boiled at 
95 °C for an additional five minutes in order to denature and linearize proteins.  
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2.8.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated by either 12% Stain-free® Fast-Cast® polyacrylamide gels 
or 15% polyacrylamide gels. The 12% gels were separated at 100 V for ten minutes 
and then 150 V for approximately one hour. The 15% gels were separated at 100 V 
for approximately two hours. The gels were then activated in the ChemiDoc™ XRS+ 
System with the Image Lab™ Software (Bio-Rad, Johannesburg, South Africa). 
Proteins were transferred onto low fluorescence polyvinylidene fluoride (LF PVDF) 
membranes Trans-Blot® Turbo™ Mini PVDF Transfer Packs (170-4156, Bio-Rad, 
Johannesburg, South Africa) using the TransBlot® Turbo™ Transfer System (Bio-
Rad, Johannesburg, South Africa) for seven minutes at 15 V. Membranes were 
blocked for one hour in 5% fat-free milk made up in Tris-Buffered Saline-Tween®20 
solution (TBS-T) at room temperature to prevent non-specific binding, and washed 
three times for five minutes in TBS-T. The membranes were incubated in primary 
antibody (Table 2.2) overnight at 4 °C with gentle agitation, after which the membranes 
were washed three times for five minutes in TBS-T and incubated for one hour in 
appropriate secondary antibody (Table 2.2) at room temperature. Membranes were 
washed three times for five minutes and incubated in ClarityTM Western ECL Substrate 
(1705061, Bio-Rad, Johannesburg, South Africa). Protein bands were detected using 
on the ChemiDoc™ XRS+ System with the Image Lab™ Software (Bio-Rad, 
Johannesburg, South Africa), and were normalised against total lane protein and 
quantified with the Image Lab™ Software (Appendix O and P).  
2.8.4 Total protein loading controls 
Although housekeeping proteins, including β-actin and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), have long been used as loading controls to ensure equal 
loading, BioRad Stain-free® technology has been shown to out-perform this traditional 
method (Rivero-Gutiérrez et al., 2014). The traditional method relies on the 
assumption that these housekeeping proteins do not change under most 
circumstances (Aldridge et al., 2008). The principle of BioRad Stain-free® technology 
lies in the polyacrylamide gel chemistry, in which a patented additive in the gel mixture 
reacts with tryptophan residues within proteins sequences, and can be visualised 
when exposed to UV radiation (Rivero-Gutiérrez et al., 2014). This modern method 
was employed to ensure equal loading across all samples were maintained. 
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Table 2.1: Primary and secondary antibodies with their appropriate dilutions. 
Abbreviations: CST (Cell Signalling Technology), Cu/Zn SOD (copper/zinc superoxide 
dismutase), MnSOD (manganese superoxide dismutase), HRP (horseradish 
peroxidase) 
Primary Antibody Company Dilution 
Molecular 
Weight 
Caspase 3 
 
CST (9662) 1:1000 17, 19, 35 
SOD1 (Cu/Zn 
SOD) 
 
CST (71G8) 1:1000 18 
SOD2 (Mn SOD) 
 
CST (13141) 1:1000 22 
Secondary 
Antibody 
  
HRP-Linked 
 
CST (7074) 1:10 000 
HRP-Linked CST (7076S) 1:10 000 
 
2.9 Statistical analysis  
GraphPad Prism software version 5.0.3 (GraphPad Inc., San Diego, CA) was used for 
statistical analysis of the data. All data were tested for normality after which the 
appropriate tests were performed. Comparisons between the different treatment 
groups were performed by either one-way analysis of variance (ANOVA) or two-way 
ANOVA where applicable, followed by the Fischer’s Least Squared Difference (LSD) 
post-hoc tests. All statistical tests were performed in consultation with an experienced 
biostatistician (Prof Daan Nel, Stellenbosch Statistical Consultation Centre, 
Stellenbosch University, South Africa).  All data are represented as mean ± standard 
error of mean (SEM). A p-value <0.05 was considered statistically significant.  
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CHAPTER 3: Results 
3.1 Food consumption, body and pancreatic weights of the animals 
As ghrelin is a known appetite stimulant, food consumption was monitored throughout 
the eight weeks of treatment. Surprisingly and most unexpectedly, the saline treated 
animals (vehicle) actually consumed more food than the ghrelin treated group (Figure 
3.1). DOX affected appetite as food consumed by DOX treated animals was 
significantly reduced (152.95 ± 10.23 g, p<0.05) from 4 weeks of treatment when 
compared to vehicle (185.30 ± 6.98 g), and this was maintained throughout the 
treatment duration (Figure 3.1). While ghrelin in the combination group modestly 
increased food consumption throughout this study when compared to the DOX group 
only, this was not statically significant. Moreover, following eight weeks of treatment, 
animals in the combination group consumed significantly less food (162.44 ± 18.46 g) 
when compared to vehicle (197.38 ± 8.85 g) which shows that ghrelin prevented loss 
of appetite induced by DOX until the eighth week of treatment. 
This study then went on to evaluate the change in body weight of the animals from the 
start of the study to the end of eight weeks of treatment. All animals gained weight by 
the end of the study (Figure 3.2 and Table 3.1). However, the change in body weight 
of the DOX treated animals was significantly lower (186.88 ± 10.35 g, p<0.0001) when 
compared to the vehicle group (304.61 ± 22.62 g) which correlates with the reduced 
food intake observed (Figure 3.1). Ghrelin alone did not cause a change in body weight 
when compared to the vehicle, but in combination with DOX it modestly increased 
body weight when compared to the DOX group, although this increase was not 
statistically significant. Furthermore, the change in body weight of the animals in the 
combination group was significantly lower (231.01 ± 8.21 g, p<0.01) than the vehicle. 
Thus, the food consumption data obtained throughout the treatment duration echoes 
the change in body weight seen at the end of the study, and highlights that while 
ghrelin in the presence of DOX prevented loss of appetite throughout the duration of 
treatment, it was unable to prevent the animals from losing weight. In addition, 
pancreatic weight was recorded after the duration of treatment and expressed as a 
ratio to final body weight, however, no significant changes were observed between the 
groups (Table 3.2). 
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Figure 3.1: Food consumed by animals throughout treatment duration. Experimental 
animals were treated with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the 
ninth week following treatment. Values are expressed as mean ± SEM (n = 7 - 9), *p<0.05, 
**p<0.01, ***p<0.001 vs V. Abbreviations: V (vehicle), G (ghrelin), D (DOX), DG 
(DOX+ghrelin).  
 
 
 
 
 
 
 
Figure 3.2: Change in body weight of animals between treatment groups following eight 
weeks of treatment. Experimental animals were treated with saline, ghrelin, DOX and 
DOX+ghrelin and were assessed on the ninth week following treatment. Values are expressed 
as mean ± SEM (n = 7 - 9), **p<0.01, **** p<0.0001 vs V. Abbreviations: V (vehicle), G 
(ghrelin), D (DOX), DG (DOX+ghrelin). 
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Table 3.1: The average initial and final body weight (grams) of animals in each treatment 
group after eight weeks of treatment. Experimental animals were treated with saline, 
ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week following treatment. 
Values are expressed as mean ± SEM (n = 7 - 9). Abbreviations: V (vehicle), G (ghrelin), D 
(DOX), DG (DOX+ghrelin).  
Treatment 
Groups 
Initial Body Weight (g) Final Body Weight (g) 
V 115.90 ± 24.87 420.50 ± 16.44 
G 82.81 ± 9.71 408.20 ± 21.30 
D 97.39 ± 6.55 281.40 ± 9.78 
DG 85.27 ± 9.87 316.30 ± 7.09 
 
Table 3.2: Average ratio of pancreatic weight to final body weight. Experimental animals 
were treated with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week 
following treatment. Values are expressed as mean ± SEM (n = 7 - 9). Abbreviations: V 
(vehicle), G (ghrelin), D (DOX), DG (DOX+ghrelin), AU (arbitrary units). 
Treatment 
groups 
V G D DG 
Pancreatic 
weight: Body 
weight (AU) 
0.003 ± 
0.0001 
0.004 ± 
0.0003 
0.004 ± 
0.0001 
0.003 ± 
0.0001 
 
3.2 Hormonal and inflammatory cytokine evaluation 
Considering that the pancreas regulated circulating blood glucose levels in the body 
with the help of insulin and glucagon, this study determined the circulating levels of 
these hormones in the serum of non-fasted animals. Although not significant, there 
was a trend towards an increase in the insulin levels of both groups of DOX treated 
animals when compared to the vehicle (Figure 3.3A), suggesting that DOX may have 
the ability to influence insulin secretion from the pancreas. Glucagon serum 
concentrations in the DOX and ghrelin treated groups were similar to that of the vehicle 
group, while the combination of both DOX and ghrelin also trended towards an 
increase, however, this was not statistically significant (Figure 3.3B). In the same 
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serum samples, inflammatory markers including TNF-α and IL-6 were also analysed 
but the concentration of both cytokines was unfortunately below the detectable range 
(1 – 62 pg/ml) of the multiplex kit utilised (data not shown). As inflammation plays an 
integral role in pancreatitis, these results do not imply that no changes occurred, but 
rather a more sensitive technique should have been applied. 
  
 
 
 
 
 
 
Figure 3.3: Serum [A] insulin and [B] glucagon concentrations of animals between 
treatment groups following eight weeks of treatment. Experimental animals were treated 
with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week following 
treatment. Values are expressed as mean ± SEM (n = 7 - 9). Abbreviations: V (vehicle), G 
(ghrelin), D (DOX), DG (DOX+ghrelin). 
3.3 Histomorphological changes induced by DOX and ghrelin treatment 
In an effort to determine the potential structural modifications induced by DOX and 
ghrelin within the islets of Langerhans, H&E staining was conducted. There were no 
noticeable changes observed between both the endocrine and exocrine tissue 
between treatment groups. The islets present with an ovoid shape and this was 
relatively maintained throughout the various treatment groups without any major 
modifications. However, it should be noted that the islets in the groups treated with 
DOX did appear to be smaller and irregularly shaped when compared to the vehicle 
group (Figure 3.4). Even though the islets displayed in this figure seem to be 
quantified, this was not the case in this study.  
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Figure 3.4: Representative H&E photomicrographs of the islets of Langerhans between 
treatment groups following eight weeks of treatment. Images were enlarged (right) and 
the islets encircled in order to assess islet shape. Experimental animals were treated with 
saline, ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week following 
treatment. Images on left: Magnification = 40 X, Scale bar = 50 µm, n = 7 – 9. Abbreviations: 
V (vehicle), G (ghrelin), D (DOX), DG (DOX+ghrelin), I (Islet of Langerhans). 
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3.4 DOX and ghrelin’s effect on collagen deposition  
The Masson’s Trichrome stain was employed to establish fibrosis within the pancreas 
and the representative images of collagen deposition are presented in Figure 3.5A. 
Both the vehicle and ghrelin groups showed relatively small amounts of collagenous 
tissue (blue areas), while a noticeable amount of collagen was observed in the DOX 
treated group when compared to the vehicle. The combination group displayed less 
collagen deposition versus the DOX group. To quantify these observations and 
statistically compare differences between groups, 20 random areas of the pancreas in 
each treatment group were imaged and analysed using Image J software. The 
collagenous areas (blue areas) were quantified and expressed as a percentage of the 
area of the entire tissue (red area). DOX was shown to induce significant collagenous 
tissue deposition (4.80 ± 0.78%, p<0.0001) when compared to the Vehicle group (1.14 
± 0.14%). Ghrelin significantly reduced the amount of collagen deposition in the 
combination group (2.22 ± 0.39%, p<0.001) when compared to the DOX group (Figure 
3.5B), therefore confirming its known anti-fibrotic effects. 
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Figure 3.5: [A] Representative images of collagen deposition (blue-stained) in the 
pancreas between treatment groups following eight weeks of treatment. Experimental 
animals were treated with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the 
ninth week following treatment. Magnification = 4 X, Scale bar = 50 µm, n = 7 – 9. 
Abbreviations: V (vehicle), G (ghrelin), D (DOX), DG (DOX+ghrelin).  
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Figure 3.5: [B] Quantitative analysis of collagen content between treatment groups 
following eight weeks of treatment. Experimental animals were treated with saline, ghrelin, 
DOX and DOX+ghrelin and were assessed on the ninth week following treatment. Values are 
expressed as mean ± SEM (n = 7 - 9), **** p<0.0001 vs V, ###p<0.001 vs DG. Abbreviations: 
V (vehicle), G (ghrelin), D (DOX), DG (DOX+ghrelin).  
3.5 Immunohistochemical evaluation of the islet composition 
Immunohistochemistry was employed to establish the percentage of glucagon-
secreting α-cells and insulin-secreting β-cells within each islet. Sequential double 
staining was utilised, where the α-cells were stained brown, and the β-cells were 
stained red/pink. Representative images of immunohistochemical stains are shown in 
Figure 3.6A. This study observed no significant changes to the number of α- and β-
cells following manual quantification of the images (Figure 3.6B & Figure 3.6C).  
Collectively, all the different histological techniques used in this study displayed no 
structural differences between treatment groups, other than collagen deposition. This 
may suggest that either the model of chronic DOX treatment used in this study was 
not severe enough to produce significant changes, or the changes were too subtle to 
be detected overall.  
 
 
[B] 
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Figure 3.6: [A] Representative immunohistochemical photomicrographs of the islets of 
Langerhans, and the percentage of [B] α-cells and [C] β-cells within each islet of 
Langerhans between treatment groups following eight weeks of treatment. Experimental 
animals were treated with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the 
ninth week following treatment. [A] Magnification = 40 X, Scale bar = 50 µm, n = 4 – 5. [B] 
Values are expressed as mean ± SEM (n = 7 – 9). Abbreviations: V (vehicle), G (ghrelin), D 
(DOX), DG (DOX+ghrelin).  
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3.6 Investigating the effects of chronic DOX and ghrelin treatments on oxidative 
stress 
The major mechanism by which DOX is believed to cause damage to other organs is 
by the generation of free radicals which induce oxidative damage and, if severe 
enough, eventually lead to apoptosis. While anti-oxidant enzymes maintain the 
balance of free radicals in cells, oxidative damage may result if the generation of free 
radical exceeds the ability of anti-oxidants to protect cells (Rahman, 2007). Therefore, 
this study measured the anti-oxidant capacity, anti-oxidant status, as well as oxidative 
damage for a holistic evaluation of oxidative stress in the different treatment groups.  
3.6.1 Anti-oxidant capacity  
The oxidative radical absorbance capacity (ORAC) was measured to establish DOX 
and ghrelin’s effects on the anti-oxidant capacity of the pancreas. As indicated in 
Figure 3.7, DOX significantly increased (0.51 ± 0.028 μmol TE/g, p<0.01) the anti-
oxidant capacity when compared to the vehicle (0.37 ± 0.05 μmol TE/g). Ghrelin, either 
alone or in the presence of DOX, did not lead to any considerable changes when 
compared to the vehicle and DOX treated groups, respectively. Moreover, this figure 
illustrates that the anti-oxidant capacity of the combination group was significantly 
higher (0.47 ± 0.01 μmol TE/g) than the vehicle group. Taken together, these results 
suggest that DOX induces oxidative stress which raises the anti-oxidant capacity of 
the pancreas while ghrelin reduces the DOX-induced oxidative stress and, thus, the 
consequent increase in anti-oxidant capacity. 
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Figure 3.7: Anti-oxidant capacity of the pancreas between treatment groups following 
eight weeks of treatment. Experimental animals were treated with saline, ghrelin, DOX and 
DOX+ghrelin and were assessed on the ninth week following treatment. Values are expressed 
as mean ± SEM (n = 7 - 9), ** p<0.01 vs V. Abbreviations: V (vehicle), G (ghrelin), D (DOX), 
DG (DOX+ghrelin), μmol TE/g (μmol of Trolox equivalent/gram of tissue). 
3.6.2 Superoxide dismutase activity and expression 
To further evaluate the effects of the different treatment regimens on specific anti-
oxidants, SOD activity and expression was determined. SOD was assessed as it is 
the most abundant anti-oxidant in the pancreas, and DOX is known to produce ROS 
in the form of O2●−, which are dismutated by SOD. DOX reduced (1.49 ± 0.18 U/mg, 
p<0.01) the overall activity of these enzymes when compared to the vehicle (2.31 ± 
0.28 U/mg) (Figure 3.8A). No changes in SOD activity were observed with ghrelin 
treatment, either alone or in combination with DOX, when compared to vehicle and 
DOX treated groups, respectively. However, SOD activity in the combination group 
was significantly reduced (1.54 ± 0.12 U/mg) when compared to the vehicle. These 
results indicate that DOX is inhibiting the activity of SOD, while treatment with ghrelin 
is preventing the inhibitory effect of DOX on SOD activity.  
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Figure 3.8: [A] SOD activity in the pancreas between treatment groups following eight 
weeks of treatment. Experimental animals were treated with saline, ghrelin, DOX and 
DOX+ghrelin and were assessed on the ninth week following treatment. Values are expressed 
as mean ± SEM (n = 7 - 9), ** p<0.01 vs V. Abbreviations: V (vehicle), G (ghrelin), D (DOX), 
DG (DOX+ghrelin), U/mg (unit inhibition/mg of protein). 
When observing protein expression of the two SOD isoforms, including SOD1 (copper 
Zinc/CuZnSOD) and SOD2 (manganese/MnSOD), different expression patterns were 
observed. SOD1 is mainly cytosolic and while no changes observed were statistically 
significant across treatment groups, there was a gradual decline in its expression 
(Figure 3.9B). SOD2, on the other hand, is mainly mitochondrial and DOX did not 
appear to affect its expression when compared to the vehicle group. Alternatively, 
although not statistically significant, ghrelin modestly increased SOD2 expression both 
alone and in the presence of DOX when compared to vehicle and DOX treated groups, 
respectively (Figure 3.9C). It is therefore likely that both DOX and ghrelin influence 
expression of SOD enzymes depending on their localisation. 
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Figure 3.8: Western blot analysis of [B] SOD1 and [C] SOD2 protein levels between 
treatment groups following eight weeks of treatment. Experimental animals were treated 
with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week following 
treatment. Values are expressed as mean ± SEM (n = 7 - 9). Abbreviations: V (vehicle), G 
(ghrelin), D (DOX), DG (DOX+ghrelin). 
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3.6.3 Glutathione assays 
Considering that the ORAC assay does not measure glutathione levels, as well as the 
fact that SOD dismutates O2●− into H2O2 which is then targeted by GPx, this study 
utilised glutathione assays to measure the levels of both the reduced (GSH) and 
oxidised (GSSG) forms of glutathione. GPx removes H2O2 by coupling its reduction 
(GSH) to H2O2 with the oxidation of glutathione (GSSG). As indicated in Table 3.3, no 
changes were observed in any of the treatment groups when GSH, GSSG and the 
ratio (GSH: GSSG) between the two were evaluated, thus demonstrating that neither 
DOX nor ghrelin treatment had any considerable effect on GPx activity in the 
pancreas. 
Table 3.3: Glutathione content in the pancreas between treatment groups following 
eight weeks of treatment. Experimental animals were treated with saline, ghrelin, DOX and 
DOX+ghrelin and were assessed on the ninth week following treatment. Values are expressed 
as mean ± SEM (n = 6 - 9). Abbreviations: V (vehicle), G (ghrelin), D (DOX), DG 
(DOX+ghrelin), AU (arbitrary unit).  
Treatment 
Group 
Vehicle Ghrelin DOX DOX+Ghrelin 
GSH (μmol/g) 102.7 ±1.42 89.55 ±4.31 95.15 ±5.05 90.62 ±6.178 
GSSG 
(μmol/g) 23.81 ±1.05 25.47 ±0.80 24.95 ±1.715 26.89 ±2.345 
GSH: GSSG 
(AU) 4.357 ±0.1876 3.55 ±0.2662 4.068 ±0.4733 3.721 ±0.5162 
 
3.6.4 Assessment of lipid peroxidation 
Lipid peroxidation is the most widely used indicator of free radical production. 
Unsaturated fatty acids, present in the cell membranes and other organelles, are a 
common target for free radicals. When fatty acids are oxidised, they produce lipid 
hydroperoxides, in which conjugated dienes (CDs) are one of the initial products 
generated that undergo further oxidation to form malondialdehyde (MDA). The results 
presented in Figure 3.9A & B show no significant changes between treatment groups, 
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which demonstrates that neither DOX nor ghrelin treatment resulted in oxidative 
damage of the pancreas following eight weeks of treatment.  
Taken together, the oxidative stress analyses used in this study indicate that while 
there was a degree of free radical production, the ROS produced was not significant 
to induce oxidative damage in the form of lipid peroxidation.  
  
 
 
 
 
 
 
 
Figure 3.9: Assessment of lipid peroxidation in which [A] conjugated dienes and [B] 
malonaldehyde concentrations were measured in the pancreas between treatment 
groups following eight weeks of treatment. Experimental animals were treated with saline, 
ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week following treatment. 
Values are expressed as mean ± SEM (n = 3 - 5). Abbreviations: V (vehicle), G (ghrelin), D 
(DOX), DG (DOX+ghrelin), μmol/g (μmol conjugated dienes/gram of tissue), μmol/L MDA 
(μmol/L of malonaldehyde).  
3.7 Evaluation of apoptosis during DOX and ghrelin treatment  
When oxidative stress exceeds the anti-oxidant capacity, apoptotic cell death is 
stimulated. This study illustrated that while total caspase-3 expression did not change 
between the treatment groups, the expression of the cleaved form of caspase-3 
produced considerable changes although not statistically significant (Figure 3.10). 
DOX treatment resulted in increased cleaved caspase-3 expression, though in the 
presence of ghrelin, its expression was reduced. These results indicate that while DOX 
is a potent cytotoxic agent, ghrelin is anti-apoptotic and thus, protective.  
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Figure 3.10: Western blot analysis of both total and cleaved caspase-3 protein levels 
between treatment groups following eight weeks of treatment. Experimental animals 
were treated with saline, ghrelin, DOX and DOX+ghrelin and were assessed on the ninth week 
following treatment. Values are expressed as mean ± SEM (n = 7 - 9). Abbreviations: V 
(vehicle), G (ghrelin), D (DOX), DG (DOX+ghrelin). 
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Chapter 4: Discussion 
The pancreas is one of the most important organs in the body as it aids in digestion 
and glucose metabolism due to the presence of exocrine and endocrine tissues, 
respectively. It is similar to other organs in that it is prone to injury induced either by 
extracellular or intracellular stimuli. DOX, a potent chemotherapeutic agent known for 
its clinical efficiency against rapidly multiplying cells, remains one of the most widely 
used anti-cancer agents for the treatment of a variety of cancers. However, DOX’s 
clinical use is limited due to its cumulative, dose-dependent toxicity, particularly in 
cardiomyocytes. This has led to literature predominately focusing on the underlying 
mechanisms involved in DOX’s toxicity in the heart and other organs, while studies 
are lacking regarding DOX’s effects on the pancreas. Therefore, the influence of DOX 
on the pancreas was investigated in this study. Furthermore, as there is no cure for 
DOX toxicity, there is no consensus nor guidelines established in the literature as to 
how this condition should be managed. Thus, this study further evaluated the 
properties of ghrelin, a brain-gut hormone best known for its appetite stimulating 
effects, which could be of potential benefit in this context. Furthermore, since DOX 
toxicity is associated with oxidative stress, apoptosis, inflammation and fibrosis, this 
study investigated ghrelin’s previously demonstrated protective properties in this 
context.  
4.1 DOX prevents weight gain while ghrelin promotes appetite 
One of the most striking features of a cancer patient undergoing chemotherapy is not 
only hair loss but also weight loss, and considering that ghrelin promotes appetite, its 
use as an adjuvant therapy in this study was promising. As indicated in Figures 3.1 
and 3.2, DOX treated animals ate significantly less food and consequently gained less 
weight, when compared to their control (vehicle) counterparts, and thereby the growth 
of these animals was stunted. The inclusion of ghrelin as part of the treatment regimen 
appears to prevent this from occurring, albeit insignificantly so. These results are in 
accordance with other in vivo studies that showed that ghrelin administration during a 
cachexic state not only stimulated appetite, increased body weight and adiposity, it 
also protected the skeletal muscles from wasting (Strassburg et al., 2008; Reano et 
al., 2014; Tschöp et al., 2000). Although the exact mechanisms underlying ghrelin’s 
orexigenic effects are still unknown, what is known is that ghrelin acts through the 
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hypothalamic-pituitary axis to promote appetite. When ghrelin is produced by the 
oxyntic gastric mucosa, it is released into circulation where it travels to the anterior 
pituitary gland and exerts its effects (Date et al., 2002; Chopin et al., 2011). In addition, 
ghrelin induces the release of GH from the pituitary to promote adipogenesis, 
proliferation and differentiation of cells, as well as the stimulation of bone growth 
(Zhang et al., 2007; Delporte, 2013). The above effects could thus be attributed to the 
increase in food consumption which promotes energy production and increased body 
weight, as well as the independent effects of GH. As there are no known toxic effects 
of ghrelin even at supraphysiological doses, it may be a promising agent that could be 
used alongside DOX to prevent cachexia and improve quality of life of patients.  
4.2 Neither DOX nor ghrelin alters pancreatic insulin and glucagon secreting 
cells 
Insulin secreted by pancreatic β-cells promotes the uptake of glucose, fatty acids and 
amino acids from the blood into peripheral tissues, including skeletal muscle and 
adipocytes, whereas glucagon secreted by pancreatic α-cells induces glucose 
production through the promotion of glycogenolysis and gluconeogenesis (Jiang & 
Zhang, 2003; Rafacho et al., 2014). Therefore, in the post-prandial state, circulating 
insulin levels are high and ghrelin levels are low in order to decrease circulating blood 
glucose levels. When insulin binds to its receptor (IR) or insulin-like growth factor-
1(IGF-1R), which are expressed at the cell surface of peripheral tissues, cytoplasmic 
insulin receptor substrate (IRS) proteins transmit signals from these receptors to 
induce a cellular response. This occurs by IRS becoming phosphorylated at the 
tyrosine residues and leads to the activation of the phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K)/Akt pathway, which triggers glucose transporter 4 
(GLUT-4) to translocate to the cell membrane, facilitating glucose uptake into the cell 
(Shaw, 2011). In the fasted state however, both glucagon and ghrelin levels are high 
in order to increase blood glucose levels. Even though our results show that there 
were no changes in the circulating levels of both insulin and glucagon in any of the 
treatment groups (Figure 3.3A & B), the levels of insulin were ±70 fold higher than 
glucagon levels. As these animals were not fasted when blood was collected, it is thus 
likely that the high insulin levels observed were as a result of the animals being in a 
fed state. Since the link between the use of chemotherapeutic drugs and the 
development of diabetes remains to be elucidated and the fact that previous studies 
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have reported that DOX treatment inhibits glucose-stimulated insulin secretion in 
isolated rat β-cells (Dispenzieri & Loprinzi, 1997; Geetha et al., 1999), this study 
merely aimed to evaluate DOX’s effects on insulin and glucagon secretion and to 
assess the role of ghrelin within this context. To investigate this further, fasted serum 
levels of insulin, glucagon and ghrelin should be taken before, during and after 
treatment with DOX. 
Damage to α- and -cells can lead to pancreatic disorders such as diabetes 
(Bachmann et al. 2011; Steer, 2012). Numerous experimental studies have shown 
that DOX is highly toxic to rodent islets and induces apoptotic cell death of β-cells 
(Zhang et al., 2007; Heart et al., 2016). In our study, ghrelin did not appear to induce 
any obvious morphological changes to the islets of Langerhans, which all displayed a 
relatively normal ovoid shape (Figure 3.4). Although the islets of Langerhans in the 
DOX treated group appeared to be smaller and irregularly shaped, these changes 
were minor. To support our findings, Saleh & Ali (2005) also illustrated that DOX 
stimulates atrophy of pancreatic cells. Furthermore, the number of α- and -cells 
contained within each islet in this study remained the same (Figure 3.6 A-C). 
Considering all of the above, the model used to simulate chronic DOX toxicity had no 
significant effect on glucagon and insulin secretion as well as the number of α- and -
cells within the islets. It is likely that our insignificant results were due to the 
concentration, frequency and duration of DOX treatment compared to other studies. 
Whereas this study treated animals with DOX once weekly (2.5 mg/kg) over eight 
weeks resulting in a cumulative dose of 20 mg/kg, Saleh & Ali (2015) treated their 
animals with a dose of 15 mg/kg for 30 days.  
4.3 Ghrelin ameliorates DOX-induced fibrosis  
Despite DOX being listed as one of the drugs associated with the development of 
pancreatitis, the mechanisms involved remain unknown (Trivedi & Pitchumoni, 2005; 
Kaurich, 2008). Pancreatitis, as mentioned previously can be categorised as acute 
pancreatitis, which is associated with inflammation, and chronic pancreatitis, in which 
fibrosis is a hallmark characteristic (Bachmann et al., 2011; Lankisch et al., 2015). 
During acute pancreatitis, obstruction or damage to the pancreatic ducts can result in 
the leakage of pancreatic digestive enzymes from acinar cells, resulting in damage to 
the pancreatic tissue and the stimulation of an inflammatory response (Jones & 
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Gorges, 1997). Serum TNF-α and IL-6 levels can be used as early markers for the 
detection of acute pancreatitis, however considering the half-life of these cytokines, 
peak serum concentrations are difficult to detect. The serum levels of TNF-α and IL-6 
in this study were below the detectable range (data not shown).  
Prolonged and continuous inflammation within the pancreas can progress to fibrosis 
often associated with chronic pancreatitits (Steer, 2012; French & Charnely, 2016). 
Although the mechanisms involved have yet to be fully determined, persistent 
activation of pancreatic stellate cells have been reported in both human and 
experimental studies, where these cells are responsible for collagen synthesis (Haber 
et al., 1999; Kozak et al., 2016). Following pancreatic injury, platelets secrete pro-
fibrotic cytokines PDGF and TGF-β1 which recruit white blood cells to the injured site. 
PDGF triggers proliferation of pancreatic stellate cells, while TGF-β1 stimulates these 
cells to produce collagen, consequently replacing damaged cells with fibrotic tissue 
(Kishi et al., 2003). In this study, treatment with DOX induced significant collagen 
deposition indicative of fibrosis (Figure 3.5A & B), while co-treatment with ghrelin 
reduced collagen deposition. In support of our observations, various studies have 
shown the anti-fibrotic effects of ghrelin administration in different contexts. Reduced 
type I and III collagen deposition following ghrelin administration has previously been 
demonstrated in injured rat kidneys (Sun et al., 2015) and following a myocardial 
infarction (Huang et al., 2009), which reduced overall fibrosis. These event are thought 
to occur through ghrelin’s anti-inflammatory effects which have been shown to 
downregulate pro-inflammatory cytokine expression in human monocytes (Dixit et al., 
2004). Therefore, this study proposes that by reducing the expression levels of pro-
inflammatory and pro-fibrotic cytokines, ghrelin exhibits similar protective effects in the 
pancreas during DOX treatment and thereby reduces collagen deposition. 
4.4 DOX induces SOD anti-oxidant activity 
As a result of inflammation, ROS generation cannot be avoided and has been 
implicated in playing a role in damaging pancreatic parenchyma, leading to fibrosis 
(Angelino et al., 2015). In this context, DOX is a potent inducer of oxidative stress due 
to its chemical structure having the ability to be oxidised and reduced, and thereby 
producing ROS (Minotti et al., 2004). This study demonstrates that the pancreas in 
response to DOX treatment elevates its anti-oxidant capacity (Figure 3.7). Although 
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this response was expected, it is a clear indication that this organ is attempting to 
protect itself against DOX-induced ROS generation. 
SOD is the most abundant anti-oxidant found in the pancreas and DOX is particularly 
known to produce ROS in the form of O2●− (Grankvist et al., 1981; Kalyanaraman et 
al., 2002).  Therefore, to determine the presence of O2●−, SOD activity was measured 
(Figure 3.8A). Our findings show that in both DOX treated groups, SOD anti-oxidant 
activity was significantly reduced. Although it is known that persistent or high levels of 
ROS can reduce anti-oxidant activity (Poljsak et al., 2013), it is relatively unknown that 
DOX can influence the expression of SOD enzymes in the pancreas (Figure 3.8B & 
C). While SOD1, which is mainly cytosolic, was reduced in all treatment groups when 
compared to the vehicle, mitochondrial SOD2 was elevated in both ghrelin treated 
groups. Despite these results being insignificant, there is a clear distinction in 
differential effects that both ghrelin and DOX have on the SOD isoforms. Whereas 
SOD1 appeared to be severely affected by DOX treatment and unaffected by ghrelin, 
SOD2 remained unchanged in the presence of DOX, its expression increased in the 
presence of ghrelin.  
The role of SOD is to dismutate O2●− to form H2O2, which is removed by catalase and 
GPx. However, H2O2 removal is influenced by where it is produced. While H2O2 
produced by enzymes in peroxisomes is usually disposed of by catalase, H2O2 
produced in the mitochondria is removed by GPx. GPx removes H2O2 by coupling its 
reduction to H2O2 with the oxidation of glutathione (Weydert & Cullen, 2010). This 
study did not observe any noteworthy changes in the status of glutathione levels in its 
reduced (GSH) nor oxidised (GSSG) forms (Table 3.3). This result was not particularly 
surprising considering that SOD activity was reduced, and thus H2O2 was not 
produced to influence the GSH levels in a significant manner. 
We also found no changes in the early and late markers of lipid peroxidation, the main 
molecular mechanism involved in oxidative damage to cell structures and the toxicity 
that leads to cell death. (Figure 3.9A & B). The first step in the initiation of lipid 
peroxidation is the production of a fatty acid radical by ROS such as OH● or 
hydroperoxyls (HOO●) radicals. As these fatty acid radicals are not very stable, they 
react with O2 to produce a peroxyl fatty acid radical. This newly formed radical is also 
not stable, and reacts with another fatty acid radical to produce a different fatty acid 
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radical and lipid peroxides. If, however, the peroxyl fatty acid radical reacts with itself, 
then cyclic peroxide is produced. This cycle continues in a chain reaction until two 
radicals react with one another to produce a non-radical (Botsoglou et al., 1994; 
Devasagayam et al., 2003). Yet to produce OH●, O2●− would have to react with H2O2 
in the presence of transition metals such as Fe; whereas to form HOO●, hydrogen 
atoms are donated to O2 or, O2 donates to OH● or, protons are donated to O2●− 
(Halliwell, 2006; Valko et al., 2006). Considering that OH● are the most reactive of all 
ROS, and no H2O2 was detected in this study (indirectly measured by GSH levels) it 
is plausible to speculate that there was an insufficient of amount ROS generated to 
induce lipid peroxidation in this study. However, OH● radicals have been observed in 
isolated rat islets (Armanna et al., 2007), but whether they are upregulated in animal 
models of inflammatory diseases and make a signiﬁcant contribution to the disease 
pathology by aggravating tissue injury, remains to be resolved. 
4.5 Anti-apoptotic effects of ghrelin against DOX-induced cell death 
Apoptotic cell death triggered by either oxidative stress, inflammation or DOX 
treatment directly, is a relevant event that occurs in this context (Sawyer et al., 1999; 
Kotamraju et al., 2000). It is well known that caspase-mediated apoptosis involves the 
cleavage of initiator and executioner caspases resulting in their activation (Poirier et 
al., 2002; Chaitanya et al., 2010). In this study, DOX considerably increased cleaved 
caspase-3 protein expression, but in the presence of ghrelin, this protein was reduced 
(Figure 3.10). Since the results from the oxidative stress analysis suggest that the 
amount of ROS was not sufficient to cause lipid peroxidation, and the inflammatory 
cytokines were undetectable, this study proposes that this ROS could have contributed 
to activating the intrinsic apoptotic pathway. There are a few ways in which this can 
be achieved. Firstly, p53-mediated apoptosis involves transcriptional regulation of 
target genes and is dependent on the Apaf-1/caspase-9 pathway, which results in 
cytochrome c release (Kim et al., 2006), though the exact mechanism remains elusive. 
Secondly, cytochrome c has a high affinity for cardiolipin, and once a shift in the 
oxidation state of cardiolipin changes as a result of ROS, cytochrome c is released 
(Paradies et al., 2014). Finally, the disruption of Ca2+ homeostasis within the ER or 
mitochondria are also known to be apoptogenic (Zhang et al., 2012; Williams et al., 
2013). All of the above events culminate in the initiation of the caspase cascade as a 
result of cytochrome c leakage. The anti-apoptotic effect of ghrelin observed from our 
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findings is in agreement with other studies where ghrelin prevented apoptosis from 
taking place in kidney cells and cardiomyocytes (Sun et al., 2015; Wang et al., 2014). 
This study therefore proposes that ghrelin exhibits its effects by protecting 
mitochondria to prevent cytochrome c release so that apoptosis can be averted. 
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CHAPTER 5: Conclusion  
DOX forms an integral part of the current chemotherapeutic treatment regimens due 
to its potency in treating various cancers. As a result of this characteristic, DOX 
remains one of the most widely used anti-neoplastic agents leading to improved 
survival rates of cancer patients. However, DOX’s efficacy is a double-edged sword 
where prolonged treatment is associated with off-target toxicity, particularly in 
cardiomyocytes. While literature over the years predominantly focused on DOX-
induced cardiotoxicity, very few studies regarding the effects of DOX on the pancreas 
are available. Although the exact mechanisms underlying DOX’s toxicity is yet to be 
elucidated, it is known that these mechanisms are distinct to its anti-neoplastic 
activities. This creates the possibility that an adjuvant treatment strategy can be 
investigated to reduce DOX’s off-target toxicity without interfering with its efficacy. Due 
to the disappointing and inconclusive results obtained in clinical trials utilising anti-
oxidants to target DOX-induced oxidative stress, a solution to this problem is yet to be 
found. Bearing the above in mind, this study approached this multi-faceted problem by 
investigating the benefits of a hormone with multi-faceted effects in this context. 
Ghrelin is a natural hormone most well-known for its appetite inducing and GH 
releasing effects. In addition, it has previously been shown to reduce oxidative stress, 
apoptosis, inflammation and fibrosis, all of which contribute to DOX toxicity. Our 
findings reveal that while ghrelin prevented weight loss by inducing food intake, and 
reduced both collagen deposition (indicative of fibrosis) and DOX-induced apoptosis 
in pancreatic tissue, it had no effect on oxidative stress overall and no definitive 
conclusions can be drawn with regards to inflammation (Figure 5.1A & B). Overall, 
while results are promising, further investigations are necessary to decipher the 
potential of ghrelin as an adjuvant treatment regimen in the context of DOX-induced 
pancreatic injury. 
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Figure 5.1: The proposed mechanisms of action of DOX and ghrelin on pancreatic 
tissue. A summary of the main findings indicating the possible effects of DOX alone [A] and 
DOX co-treated with ghrelin [B]. Abbreviations: ROS (reactive oxygen species), DOX 
(Doxorubicin), ↑ (increases), ↓ (decreases). 
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5.1 Limitations and future direction  
As far as we are aware, this study is one of very few studies investigating the effects 
of DOX treatment on the pancreas in a model simulating chronic DOX-induced 
cardiotoxicity. The fact that clinically relevant dosages of DOX were used in this study 
further strengthens its originality and highlights its importance in reducing the gap that 
exists in the literature. While ghrelin’s beneficial properties have been demonstrated 
in other organs, it has been relatively unknown whether the same effects would be 
observed in the pancreas. Due to the fact that there are limited studies available to 
support the results obtained in this study, we suggest that a larger sample size be 
utilised to strengthen the obvious trends observed. This will not only ensure a better 
understanding of DOX’s effects on the pancreas, but also the role that ghrelin plays in 
this context. As there was a long period from the time that blood was collected to the 
time of analysis, and the fact that inflammatory cytokines have a short half-life, in hind 
sight blood should be have been collected between 12 and 24 hours after the last dose 
of DOX and ghrelin and immediately analysed. In addition, to measure circulating 
hormones of the pancreas, the animals should be fasted for at least 24 hours, and 
ghrelin could be included as part of the analysis. The size of the islets in the different 
treatment groups could also be measured to give an indication as to whether the islets 
are undergoing atrophy. Finally, GPx and apoptotic activity assays should be taken 
into account to supplement the protein expression already obtained. 
The future recommendations of this study are vast as there are a multitude of 
questions to be answered. If funding constraints are not considered, additional animals 
could be included in the study design where some are sacrificed after 24 hours, one 
week, five weeks and at the end of the treatment protocol. With an increase in sample 
size, fasted blood samples could be collected after each treatment dosage and serum 
levels of insulin, glucagon, ghrelin, somatostatin and pancreatic polypeptide could be 
determined to indicate any changes that occurred over eight weeks of treatment. To 
determine pancreatitis, serum lipase and amylase enzymes as well as CRP levels 
could be measured as a possible indication of pancreatitis as these are all elevated 
during this condition. With the analysis of protein expression via Western blotting, a 
better approach would be to separate the cellular fractions (mitochondrial, cytosolic 
and membrane). This would enable improved understanding of the molecular events 
that take place and also how ghrelin induces its actions. Furthermore, desmin and α-
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SMA fluorescent staining could be performed to understand the role of pancreatic 
stellate cells in contributing to fibrosis. As DOX treatment is known to induce gender 
specific changes, a female cohort could be added since DOX is one of the main 
treatments for breast cancer. Finally, since the aim of this study was to investigate the 
whether ghrelin can counteract DOX’s cytotoxic effects, it is important to establish the 
effect of ghrelin on cancer cell proliferation and survival. 
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APPENDICES  
APPENDIX A: Ethical clearance letter 
 
 
Approved with Stipulations 
Date: 29-Apr-2016 
PI Name: Goldswain, Toni T Protocol #: SU-ACUD15-00038 
Title: Investigating the role of the RISK and SAFE pathways, through ghrelin stimulation, in an in vivo rat model 
of chronic Doxorubicin-induced cardiotoxicity. 
Dear Toni Goldswain, the Response to Modiﬁcations submission was reviewed on 26-Apr-2016 by Research 
Ethics Committee: Animal Care and Use via committee review procedures and was approved on condition that 
the following stipulations are adhered to: 
1. South African Veterinary Council authorisation for Dr Bester is not addressed in the response to modiﬁcation. 
Sodium Pentobarbital is a scheduled substance, the committee recommend a suitable person be responsible for 
euthanasia using this substance. By suitable, referring to a person registered with SAVC or alternatively 
authorised by SAVC to do this procedure. 
Applicants are reminded that they are expected to comply with accepted standards for the use of animals 
in research and teaching as reﬂected in the South African National Standards 10386: 2008. The SANS 
10386: 2008 document is available on the Division for Research Developments website 
www.sun.ac.za/research. 
As provided for in the Veterinary and Para-Veterinary Professions Act, 1982. It is the principal investigator's 
responsibility to ensure that all study participants are registered with or have been authorised by the South African 
Veterinary Council (SAVC) to perform the procedures on animals, or will be performing the procedures under 
the direct and continuous supervision of a SAVC-registered veterinary professional or SAVC-registered para-
veterinary professional, who are acting within the scope of practice for their profession. 
Please remember to use your protocol number, SU-ACUD15-00038 on any documents or correspondence 
with the REC: ACU concerning your research protocol. 
Any event not consis10t with routine expected outcomes that results in any unexpected animal welfare issue 
(death, disease, or prolonged distress) or human health risks (zoonotic disease or exposure, injuries) must be 
reported to the committee, by creating an Adverse Event submission within the system. 
If you have any questions or need further help, please contact the REC: ACU secretariat at 
WABEUKES@SUN.AC.ZA or 0218089003. 
Sincerely,  
Winston Beukes  
REC: ACU Secretariat  
Research Ethics Committee: Animal Care and Use 
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APPENDIX B: Preparation of ghrelin and Doxorubicin 
Materials & Reagents: 
• Ghrelin, rat (G2869, LKT® Laboratories, Inc., St. Paul, Minnesota, 
USA) 
• Doxorubicin Hydrochloride (D5794, LKT® Laboratories, Inc., St. Paul, Minnesota, 
USA) 
• Physiological Saline  
• Syringes 
• Gloves 
Ghrelin Preparation: 
• Resuspended 5 mg of ghrelin in 5 ml of sterile saline to yield a stock solution of 1 
mg/ml = 1 μg/μl. Vortexed solution thoroughly.  
• Animal dose = 100 μg/kg  
= 0.1 μg/g 
For example: 
Animal weight: 118.1 g 
= 118.1 g x 0.1 µg/g 
= 11.81 µg ghrelin 
 
Therefore, 
1 µg 
1 µl
=  
11.81 µg
𝑋
 
x = 11.81 µl ghrelin stock (1 µg/ µl) in 200 µl saline (200 µl is the injection 
volume) 
But, to account for bubble and wastage, multiplied by 2: 
Stock = 1 µg/ µL 
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11.81 µl x 2 = 23.62 µl ghrelin in 376.38 µl saline. 
Vortex solution thoroughly and injected animals with 200 µl 
DOX Preparation:  
• Resuspended 50 mg of DOX in 12.5 ml of sterile saline to yield a stock solution of 
4 mg/ml = 4 μg/μl. Vortexed solution thoroughly.  
• Animal dose  = 2.5 mg/kg 
= 2.5 μg/g 
For example: 
Animal weight: 118.1 g 
= 118.1 g x 2.5 µg/g 
= 295.25 µg DOX 
 
Therefore, 
4 µg 
1 µl
=  
295.25 µg
𝑋
 
x = 73.8125 µl DOX stock (4 µg/ µl) in 200 µl saline (200 µl is the injection 
volume) 
But, to account for bubble and wastage, multiplied by 2: 
73.8125 µl x 2 = 147.625 µl ghrelin in 252.375 µl saline 
Vortex solution thoroughly and injected animals with 200 µl. 
APPENDIX C: Serum collection  
• After the last injection (eight weeks), the animals were transported to the Cape 
Peninsula University of Technology (CPUT) 
Stock = 4 µg/ µL 
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• Following a week of acclimatisation, the animals were weighed and anaesthetised 
with a lethal dose of sodium pentobarbitone (60 mg/kg), (Euthapent, 130540, Kyron 
Laboratories, Johannesburg, South Africa), which was injected intraperitoneally 
• When pedal reflex was no longer observed, the abdominal cavity was cut open and 
blood was aspirated from the thoracic cavity, using a sterile syringe, while the heart 
was being removed from the abdominal cavity 
• Collected blood was placed into serum separation tubes (VGRV450470R, Lasec, 
Cape Town, South Africa) without anti-coagulant 
• Serum tubes were immediately placed on ice and blood was allowed to clot for 15 
- 20 minutes  
• Serum tubes were then centrifuged for 10 minutes at 4 000 rpm (1 400 x g) at 4 
°C.  
• The serum was then aliquoted into centrifuge tubes and stored at – 80 °C 
APPENDIX D: Metabolic parameters analysis  
Reagents Supplied in Milliplex® MAP Kit:  
Reagents Catalogue number Volume Quality 
Rat Metabolic 
Hormone Standard 
RMH-8084 Lyophilized 1 vial 
Rat Metabolic 
Hormone Quality 
Controls 1 and 2 
RMH-6084 Lyophilized 2 vials 
Set of one 96-well 
black plate with 2 
sealers 
- - 
1 plate 
2 sealers 
Assay Buffer LE-ABGLP 30 ml 1 bottle 
Serum Matrix LRGT-SM 1 ml 1 bottle 
Bead Diluent LE-BD 3.5 ml 1 bottle 
10 X Wash Buffer L-WB 60 ml 1 bottle 
Rat Metabolic 
Hormone Detection 
Antibodies 
RMH-1084 5.5 ml 1 bottle 
Mixing Bottle - - 1 bottle 
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Preparation of Reagents for Immunoassay: 
• Preparation of Antibody-Immobilized Beads: 
o Vortexed antibody-bead vials for 1 minute 
o Added 150 µl from each of the 6 beads vials to the Mixing Bottle. Then added 
2100 µl Bead Diluent to make a final volume of 3 ml 
o Vortexed beads well 
• Preparation of Quality Controls: 
o Added 250 µl deionised water to Quality Control 1 and Quality Control 2 
o Mixed and vortexed well 
o Allowed vial to sit for 5 – 10 minutes 
o Vortexed and transferred to labelled Centrifuge tubes 
• Preparation of Wash Buffer: 
o Allowed 10 X wash buffer to come to room temperature and mixed to bring all 
salts into solution 
o Diluted 60 ml of 10 X Wash Buffer with 540 ml deionized water  
• Preparation of Serum Matrix  
o Added 1 ml of deionised water to bottle containing lyophilized serum Matric  
o Mixed well and allowed at least 10 minutes for complete reconstitution  
• Preparation of Rat Metabolic Hormone Standard  
o Added 250 µl deionised water to the Rat Metabolic Hormone Standard 
o Mixed well and vortexed for 10 seconds  
o Allowed to sit for 5 - 10 minutes, and then vortexed and transferred this standard 
to the centrifuge tubes labelled Standard 7 
o The preparation of the working standards was as follows: 
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Standard Tube 
Volume of Deionised 
Water to add (µl) 
Volume of Standard 
to add (µl) 
S7 250 0 
S6 200 100 of S7 
S5 200 100 of S6 
S4 200 100 of S5 
S3 200 100 of S4 
S2 200 100 of S3 
S1 200 100 of S2 
 
• After performing three times serial dilutions, the standard tubes had the following 
concentrations for constructing standard curves: 
Standard Tube 
Glucagon, TNFα 
(pg/ml) 
IL-6, Insulin, (pg/ml) 
1 14 69 
2 41 206 
3 124 617 
4 370 1 852 
5 1 111 5 556 
6 3 333 16 667 
7 10 000 50 000 
 
Method:  
• The serum centrifuge tubes were thawed to room temperature 
• The centrifuge tubes were centrifuged at 3000 rpm (800 x g) for 5 minutes at 4 °C. 
• Added 200 µl of Assay Buffer to each well and swirled plated around in order to 
pre-wet the plate with Assay Buffer 
• Contents were decanted  
• Added 25 µl of Serum Matrix Solution to blank, standard, and quality control wells 
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• Added 25 µl of Assay Buffer to blank and sample wells 
• Added 25 µl of Standard and Quality Control solutions to appropriate wells  
• Added 25 µl samples to appropriate wells  
• Added 25 µl of Beads Solution to each well 
• Sealed the plate with plate sealed and covered in foil 
• Placed plate on Orbit™ P4 Digital Shaker (serial number 14061102, Labnet 
International, Inc., North America) at 550 rpm and incubated overnight at 4 °C. 
• Plate con10ts were removed and washed three times with Wash Buffer using a 
Bio-Plex Pro™ Wash Station (BioRad, Johannesburg, South Africa) 
• Added 50 µl of Detection Antibodies to each well 
• Sealed the plate with plate sealed and covered in foil 
• Placed the plate shaker at 600 rpm and incubated for 30 minutes at room 
temperature  
• Added 50 µl of Streptavidin-Phycoerythrin to each well 
• Sealed the plate with plate sealed and covered in foil 
• Placed the plate shaker at 600 rpm and incubated for 30 minutes at room 
temperature  
• Plate con10ts were removed and washed three times as previously described 
• Added 100 µl of MAGPIX® Drive Fluid (40-50013, Luminex) to each well 
• Placed the plate shaker at 600 rpm for 5 minutes to resuspend the beads 
• Placed the plate into Bio-Plex® MAGPIX™ Multiplex reader (MAGPIX13046704, 
BioRad, Johannesburg, South Africa) 
• Results were acquired results using Manager™ MP (BioRa, Johannesburg, South 
Africa) and analysed using BioPlex Manager™ Software version 6.1 (BioRad, 
Johannesburg, South Africa)  
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• Plate set up was as follows: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 4 QC1 C3 V4 G5 D7 DG4 V2 G2 D2 DG2 
B 0 4 QC1 C3 V4 G5 D7 DG4 V2 G2 D2 DG2 
C 1 5 QC2 C5 V5 G6 D8 DG5 V3 G3 D3 DG3 
D 1 5 QC2 C5 V5 G6 D8 DG5 V3 G3 D3 DG3 
E 2 6 C1 C6 V6 D5 D9 DG7 V4 G4 D4 DG4 
F 2 6 C1 C6 V6 D5 D9 DG7 V4 G4 D4 DG4 
G 3 7 C2 C7 G4 D6 DG2 V1 G1 D1 DG1 DG5 
H 3 7 C2 C7 G4 D6 DG2 V1 G1 D1 DG1 DG5 
 
Rat Metabolic Hormone Antibody Immobilised Magnetic Beads: 
Bead/Analyte Name 
Luminex® Magnetic Bead 
Region 
Catalogue Number 
Anti-Glucagon Beads 33 HGLU-MAG 
Anti-IL-6 Beads 35 RIL6-MAG 
Anti-Insulin Beads 37 RMINS-MAG 
Anti-TNFα Beads 65 RMTNFA-MAG 
 
APPENDIX E: Standard histological processing protocol 
Materials & Reagents: 
• Alcohol (70%, 90%, 95%, 100%) 
• Xylene (1330-20-7, Sigma-Aldrich, St Louis, USA) 
• Paraplast® wax (A6330-4LB, Sigma-Aldrich, St Louis, USA, melting point 56°C) 
• Embedding cassettes with lid (Z672122, Sigma-Aldrich, St Louis, USA) 
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• Leica Modular Tissue Embedding Centre (EG1150, Lecia Biosystems, 
Biosystems, Wetzlar, Germany) 
• Paraffin wax moulds  
Method: 
1. Fixed tissue in 4% formaldehyde solution (100496, Merck Millipore, 
Massachusetts, USA) in small labelled containers 
2. Followed automated tissue processing protocol 
• After 20-hour processing period, the tissues were removed from their cassettes 
and embedded in paraffin wax 
Automated tissue processing protocol:  
Step Solution Time (hours) 
Dehydration 
70% alcohol 1.5 
70% alcohol 1.5 
90% alcohol 1.5 
95% alcohol 1.5 
95% alcohol 1.5 
100% alcohol 1.5 
100% alcohol 1.5 
100% alcohol 2 
Clearing Xylene 1.5 
 Xylene 2 
Impregnation Paraffin wax 2 
 Paraffin wax 2 
Total processing time 20 
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APPENDIX F: Haematoxylin & Eosin (H&E) staining protocol 
Materials & Reagents: 
1. Manual microtome (RM 2125 RT, Leica Biosystems, Wetzlar, Germany)  
2. Leica Auto Stainer XL (ST5010, Leica Biosystems, Wetzlar, Germany  
3. Microscope slides (GLAS4S22M3000F, Lasec, Cape Town, South Africa)  
4. Microscope coverslips (GLAS2C9M2250REC, Lasec, Cape Town, South Africa) 
5. DPX mountant (06522, Sigma-Aldrich, St Louis, USA) 
6. Xylene (1330-20-7, Sigma-Aldrich, St Louis, USA)  
7. Mayer’s Haematoxylin solution (SAAR2822001LC, Merck Millipore, 
Massachusetts, USA)  
8. Eosin solution (3801600E, Leica Biosystems, Wetzlar, Germany)   
Method:  
• Sectioned tissue at 5 μm thickness using a manual microtome and transferred to 
appropriately labelled slides 
• Microscope slides were put into plastic rack and placed into the auto stainer 
machine following the pre-programmed protocol  
• After staining, mounted the coverslips with DPX mountant 
Pre-programmed H&E staining protocol: 
Step Solution Time Repetitions 
1 Xylene 10 minutes 2 
2 Ethanol (99%) 5 minutes 2 
3 Ethanol (96%) 2 minutes 1 
4 Ethanol (70%) 2 minutes 1 
5 Distilled water 5 seconds 1 
6 Haematoxylin 8 minutes 1 
Stellenbosch University  https://scholar.sun.ac.za
114 
 
7 Running water 5 minutes 1 
8 
Ethanol (1% acid 
alcohol) 
30 seconds 1 
9 Running water 1 minutes 1 
10 Ammonia (0.2%) 45 seconds 1 
11 Running water 5 minutes 2 
12 Ethanol (96%) 10 dips 1 
13 Eosin 45 seconds 1 
14 Ethanol (96%) 5 minutes 2 
15 Xylene 5 minutes 2 
 
APPENDIX G: Masson Trichrome staining protocol 
Control: Skin   
Staining Solutions: 
• Mayer’s Haematoxylin solution (SAAR2822001LC, Merck Millipore, 
Massachusetts, USA) Acetic Acid Water:  
o 2 ml Glacial acetic acid 
o 100 ml Distilled water 
• Masson Fuchson Ponceau-Orange G: 
o Stock Solution  
▪ 2 g Ponceau (2R) de xylidine 
▪ 1 g Acid fuchsin 
▪ 2 g Orange G 
▪ 300 ml 0.2% Acetic acid water  
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• Working solution     
▪ 10 ml No.3 (MFPOG) 
▪ 90 ml 0.2% Acetic acid water 
• 0.1% Light Green Solution 
• 0.1 g Light green  
• 100 ml 0.2% Acetic acid water  
• Phosphotungstic acid 5% 
• 5 g Phosphotungstic acid 
• 100 ml Distilled water 
Materials: 
• Positively charged Histobond microscope slides (GLAS2S13M0810401, Lasec, 
Cape Town, South Africa) 
• Microscope coverslips (GLAS2C9M2250REC, Lasec, Cape Town, South Africa) 
• DPX mountant (06522, Sigma-Aldrich, St Louis, USA) 
Method: 
• Sectioned tissue at 5 µm thickness using a manual microtome and transferred to 
appropriately labelled slides 
• Microscope slides were put into plastic rack and a manual deparaffinization 
process was followed 
• After staining, mounted the coverslips with DPX mountant 
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Manual Deparaffinization: 
Step Solution Time Repetitions 
1 Xylene 5 mins 2 
2 Ethanol (99%) 5 mins 2 
3 Ethanol (96%) 5 mins 2 
4 Ethanol (70%) 5 mins 2 
5 Water 3 mins  1 
 
Staining Procedure: 
1. Rinsed slides that have been deparaffinised in distilled water. 
2. Stained in haematoxylin for 5 minutes. 
3. Placed in tap water for 3 minutes till dark blue and rinse in distilled water. 
4. Stained the sections in filtered working solution of fuchsin ponceau-orange G for 5 
- 30 minutes. 
5. Rinsed in acetic acid water. 
6. Mordant in 5% phosphotungtic acid solution for 5 minutes. 
7. Rinsed in acetic acid water for 1 minute to eliminate the phosphotungstic acid and 
differentiate the colour tones. 
8. Stained in light green solution for 5 - 20 minutes.  
9. Treated with acetic acid water for 5 minutes 
10. Dehydrated through alcohols with (70%, 96%, 99% ethanol) 
11. Cleared in xylene and mounted the coverslips with DPX mounting medium  
Result: 
Nuclei  - black 
Cytoplasm      -    red 
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Collagen - green 
Mucin  - green 
Erythrocytes - yellow to orange 
APPENDIX H: Immunohistochemistry (IHC) staining protocol 
Materials & Reagents: 
1. Positively charged Histobond microscope slides (GLAS2S13M0810401, Lasec, 
Cape Town, South Africa) 
2. Microscope coverslips (GLAS2C9M2250REC, Lasec, Cape Town, South Africa) 
3. DPX mountant (06522, Sigma-Aldrich, St Louis, USA) 
4. Bond™ Polymer Refine Detection Kit (DS9800, Leica Biosystems, Wetzlar, 
Germany) 
5. Bond™ Polymer Refine Red Detection Kit (DS9390, Leica Biosystems, Wetzlar, 
Germany) 
6. Leica Bond-Max™ Immuno-Autostainer (ST5010, Lecia Biosystems, Wetzlar, 
Germany) 
7. BONDTM Software ©2009, Version 4.0 (Lecia Biosystems, Wetzlar, Germany) 
Method: 
• Sectioned tissue at 5 µm thickness using a manual microtome and transferred to 
appropriately labelled slides 
• Microscope slides were put into plastic rack and placed using the immune-
autostainer machine following the pre-programmed protocol  
• After staining, mounted the coverslips with DPX mountant 
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Automated IHC double staining protocol: 
Step Solution Time Temperature 
1 Bond Wash Solution 0 minutes 72°C 
2 Bond Wash Solution 0 minutes 72°C 
3 Bond Wash Solution 0 minutes Ambient 
4 Alcohol 0 minutes Ambient 
5 Alcohol 0 minutes Ambient 
6 Alcohol 0 minutes Ambient 
7 Bond Wash Solution 0 minutes Ambient 
8 Bond Wash Solution 0 minutes Ambient 
9 Bond Wash Solution 0 minutes Ambient 
10 
Bond ER Wash Solution 
1 
0 minutes Ambient 
11 
Bond ER Wash Solution 
1 
0 minutes Ambient 
12 
Bond ER Wash Solution 
1 
20 minutes 100°C 
13 
Bond ER Wash Solution 
1 
12 minutes Ambient 
14 Bond Wash Solution 0 minutes 35°C 
15 Bond Wash Solution 0 minutes 35°C 
16 Bond Wash Solution 0 minutes 35°C 
17 Bond Wash Solution 3 minutes Ambient 
18 Peroxide Block 5 minutes Ambient 
19 Bond Wash Solution 0 minutes Ambient 
20 Bond Wash Solution 0 minutes Ambient 
21 Bond Wash Solution 0 minutes Ambient 
22 Primary Antibody 1 30 minutes Ambient 
23 Bond Wash Solution 0 minutes Ambient 
24 Bond Wash Solution 0 minutes Ambient 
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25 Bond Wash Solution 0 minutes Ambient 
26 Post Primary 8 minutes Ambient 
27 Bond Wash Solution 2 m minutes Ambient 
28 Bond Wash Solution 2 minutes Ambient 
29 Bond Wash Solution 2 minutes Ambient 
30 Polymer 8 minutes Ambient 
31 Bond Wash Solution 2 minutes Ambient 
32 Bond Wash Solution 2 minutes Ambient 
33 Deionised Water 0 minutes Ambient 
34 Mixed DAB Refine 0 minutes Ambient 
35 Mixed DAB Refine 10 minutes Ambient 
36 Deionised Water 0 minutes Ambient 
37 Deionised Water 0 minutes Ambient 
38 Deionised Water 0 minutes Ambient 
39 Haematoxylin 5 minutes Ambient 
40 Deionised Water 0 minutes Ambient 
41 Bond Wash Solution 0 minutes Ambient 
42 Deionised Water 0 minutes Ambient 
43 Primary Antibody 2 15 minutes Ambient 
44 Bond Wash Solution 0 minutes Ambient 
45 Bond Wash Solution 0 minutes Ambient 
46 Bond Wash Solution 0 minutes Ambient 
47 Post Primary AP 20 minutes Ambient 
48 Bond Wash Solution 2 minutes Ambient 
49 Bond Wash Solution 2 minutes Ambient 
50 Bond Wash Solution 2 minutes Ambient 
51 Polymer AP 30 minutes Ambient 
52 Bond Wash Solution 2 minutes Ambient 
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53 Bond Wash Solution 2 minutes Ambient 
54 Bond Wash Solution 5 minutes Ambient 
55 Bond Wash Solution 2 minutes Ambient 
56 Bond Wash Solution 0 minutes Ambient 
57 Deionised Water 0 minutes Ambient 
58 Mixed Red Refine 10 minutes Ambient 
59 Mixed Red Refine 5 minutes Ambient 
60 Deionised Water 0 minutes Ambient 
61 Deionised Water 0 minutes Ambient 
62 Deionised Water 0 minutes Ambient 
63 Haematoxylin 5 minutes Ambient 
64 Deionised Water 0 minutes Ambient 
65 Bond Wash Solution 0 minutes Ambient 
66 Deionised Water 0 minutes Ambient 
 
Manual rehydration protocol: 
Step Solution Time Repetitions 
1 Ethanol (70%) 5 dips 1 
2 Ethanol (96%) 5 dips 1 
3 Ethanol (99%) 5 dips 1 
4 Xylene 1 min 2 
Antibodies used for IHC staining: 
Antibody Company 
Antibody 
Catalogue 
number 
Clonality Raised in Dilution 
Anti-insulin Abcam ab181547 Monoclonal Mouse 1:1000 
Anti-glucagon Abcam ab113694 Monoclonal Rabbit 1:1500 
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APPENDIX I: Oxidative Stress Assays 
Preparation of Reagents: 
• 50 mM of phosphate buffer: 
o Dissolved in 50 ml distilled water: 
▪ 0.7098 g of sodium phosphate monobasic (NaH2PO4, S8282, Sigma-
Aldrich, St Louis, USA)  
▪ 0.029 g of Ethylenediaminetetraacetic acid (EDTA, EDS-100G, 
Sigma-Aldrich, St Louis, USA)  
o Adjusted the pH to 7.5 
o Adjusted final volume to 100 ml 
• 1-methyl-2-vinylpyridinium (M2VP) 
o Made up 0.1 M HCl: 
▪ Added 4.91 ml HCl (SAAR3063040LP, Merck Millipore, 
Massachusetts, USA) to 500 ml distilled water  
o Added 12.5 ml of 0.1 M HCl to 100 mg M2VP (69701, Sigma-Aldrich, St 
Louis, USA) 
o Vortexed thoroughly  
Preparation of samples: 
• Stored the harvested tissues at - 80 °C in labelled centrifuge tubes 
• Each pancreas was carefully crushed using a sterile mortar and pestle on ice and 
separated into chilled centrifuge tubes 
• For the ORAC, SOD, GSH, and conjugated dienes assays: approximately 100 mg 
of tissue was weighed and transferred into new chilled Centrifuge tubes and 50 
mM of phosphate buffer was added into each centrifuge tube 
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o Phosphate buffer was added in a ratio of 1 000 μl phosphate buffer to 100 
mg of sample 
• For the GSSG assay: approximately 100 mg of tissue was weighed and transferred 
into new chilled centrifuge tubes and 50 mM of phosphate buffer and M2VP was 
added into each centrifuge tube 
o The exact weight of tissue was recorded  
o Phosphate buffer was added in a ratio of 1 000 μl phosphate buffer to 100 
mg of sample 
• Con10ts of each centrifuge tube were homogenised on ice in an attempt to avoid 
heating of the con10ts 
• The centrifuge tubes were centrifuged at 14 000 rpm (16 000 x g) at 4 °C for 10 
minutes. 
• The supernatant was transferred to new centrifuge tubes and frozen at – 80 °C 
APPENDIX J: ORAC (Oxygen Radical Antioxidant Reactive Capacity) assay 
Preparation of Reagents: 
• Fluorescein (F6377, Sigma-Aldrich, St Louis, USA) Stock: 
o Dissolved 0.0225 g in 50 ml of phosphate buffer 
o Can be stored at 4 °C in a brown bottle and can be reused for 1 year 
• Fluorescein Working Solution: 
o Added 10 µl of the stock to 2 ml of phosphate buffer in a falcon tube 
o Took 240 µl of this and diluted it in 15 ml of phosphate buffer in new falcon 
tube 
• 25 mg/ml 2,2'-Azobis(2-methyl-propionamidine) dihydrochloride (AAPH) peroxyl 
radical (440914, Sigma-Aldrich, St Louis, USA): 
o Weighed 150 mg of AAPH in a falcon tube and added 6 ml of phosphate 
buffer to the falcon tube 
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• 250 µM stock Trolox (standard) (238831, Sigma-Aldrich, St Louis, USA): 
o Weighed 0.00312 g in a falcon tube and added 50 ml of phosphate buffer 
Method:  
• The centrifuge tubes were thawed on ice, and then centrifuged at 14 000 rpm 
(16 000 x g) for 10 minutes at 4 °C 
• 100 µl of homogenate was added to new centrifuge tubes, and 100 µl of perchloric 
acid (PCA) was then added to each centrifuge tube 
• Standards were prepared as follows: 
Tube 
Concentration 
(μM) 
Trolox (μl) 
Phosphate 
Buffer (μl) 
(Blank) 1 0 0 750 
2 83 125 625 
3 167 250 500 
4 250 375 375 
5 333 500 250 
6 417 625 125 
 
• A 96-well black plate was used for the assay. First, second and last columns (1, 2, 
12) of plate were not used. 
• Set up of plate 1:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A   1 1 1 2 2 2 3 3 3  
B   4 4 4 5 5 5 6 6 6  
C   C5 C5 C5 C6 C6 C6 C7 C7 C7  
D   V4 V4 V4 V5 V5 V5 V6 V6 V6  
E   G4 G4 G4 G5 G5 G5 G6 G6 G6  
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F   D5 D5 D5 D6 D6 D6 D7 D7 D7  
G   D8 D8 D8 D9 D9 D9 DG2 DG2 DG2  
H   DG4 DG4 DG4 DG5 DG5 DG5 DG7 DG7 DG7  
• Set up of plate 2: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A   1 1 1 2 2 2 3 3 3  
B   4 4 4 5 5 5 6 6 6  
C   V1 V1 V1 V2 V2 V2 V3 V3 V3  
D   V4 V4 V4 G1 G1 G1 G3 G3 G3  
E   G4 G4 G4 D1 D1 D1 D2 D2 D2  
F   D3 D3 D3 D4 D4 D4 DG1 DG1 DG1  
G   DG2 DG2 DG2 DG3 DG3 DG3 DG4 DG4 DG4  
H   DG5 DG5 DG5        
 
• Added 12 µl of standards into standard wells  
• Added 12 µl of sample into sample wells  
• Added 138 µl of fluorescein solution using a multichannel into all wells 
• At the plate reader machine, added 50 µl of AAPH using a multichannel into all 
wells 
• Placed plate immediately into Fluoroskan AscentTM microplate fluometer (5210470, 
Thermo Fishcher Scientific, Massachusetts, USA) 
• Read plate every five minutes for two hours  
o Excitation wavelength for fluorescein = 485 nm 
o Emission wavelength for fluorescein = 538 nm  
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APPENDIX K: Superoxide Dismutase (SOD) assay 
Preparation of Reagents: 
• 6-Hydroxydopamine (6-HD) + PCA solution: 
o Added 50 µl PCA (100514, Merck Millipore, Massachusetts, USA) to 10 ml 
of distilled water 
o Added 10 ml of this solution and to 4 mg 6-HD (162957, Sigma-Aldrich, St 
Louis, USA)  
o Wrapped falcon tube in foil and stored on ice 
• Diethylenetriaminepentaacetic acid (DETAPAC): 
• Added 2 mg of DETAPAC (D6518, Sigma-Aldrich, St Louis, USA) to 50 ml 
of phosphate solution  
Method:  
• The centrifuge tubes were thawed on ice and then centrifuged at 12 000 rpm 
(13 300 x g) for 10 minutes at 4 °C 
• Set up of plate 1: 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Blan
k 
Blan
k 
Blan
k 
C5 C5 C5 C6 C6 C6 C7 C7 C7 
B V4 V4 V4 V5 V5 V5 V6 V6 V6 G4 G4 G4 
C G5 G5 G5 G6 G6 G6 D5 D5 D5 D6 D6 D6 
D D7 D7 D7 D8 D8 D8 D9 D9 D9 DG2 DG2 DG2 
E DG4 DG4 DG4 DG5 DG5 DG5 DG7 DG7 DG7    
F             
G             
H             
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• Set up of plate 2:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank Blank V1 V1 V1 V2 V2 V2 V3 V3 V3 
B V4 V4 V4 G1 G1 G1 G3 G3 G3 G4 G4 G4 
C D1 D1 D1 D2 D2 D2 D3 D3 D3 D4 D4 D4 
D DG1 DG1 DG1 DG2 DG2 DG2 DG3 DG3 DG3 DG4 DG4 DG4 
E DG5 DG5 DG5          
F             
G             
H             
 
• Added 12 µl of SOD assay buffer into blank wells  
• Added 12 µl of samples in sample wells 
• Added 15 µl of 6-HD + PCA solution into all wells  
• At the machine, 170 µl DETAPAC was added to all wells and the plate was read 
immediately at 490 nm 
APPENDIX L: Glutathione assays (GSH and GSSG) 
Preparation of Reagents: 
• Glutathione reductase (GR, G3664, Sigma-Aldrich, St Louis, USA) 
o Add 80 µl of glutathione reductase to 4920 µl of phosphate buffer 
• 5 5'-dithiobis-(2-nitrobenzoic acid) (DTNB, D218200, Sigma-Aldrich, St Louis, 
USA) 
o Added 6 mg to 50 ml of phosphate buffer 
• NADPH, reduced disodium salt (N6785, Sigma-Aldrich, St Louis, USA) 
o Added 12 ml of phosphate buffer straight into the NADPH bottle 
• Glutathione (GSH) (Standard): 3uM 
o Weighed 0.046 g of GSH stock and added to 50 ml of phosphate buffer in a 
falcon tube 
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o Then took 50 µl of this and diluted in 50 ml of phosphate buffer in a new 
falcon tube 
For GSH: 
Method:  
• The centrifuge tubes were thawed on ice and then centrifuged at 14 000 rpm 
(16 000 x g) for 10 minutes at 4 °C 
• GSH standards were prepared as follows: 
Tube GSH (μl) Buffer A (μl) 
(Blank) 1 0 1000 
2 167 833 
3 334 667 
4 500 500 
5 667 334 
6 833 167 
 
• A 96-well clear plate was used for this assay 
• Set up of plate 1:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 2 2 2 3 3 3 4 4 4 
B 5 5 5 6 6 6 C5 C5 C5 C6 C6 C6 
C C7 C7 C7 V4 V4 V4 V5 V5 V5 V6 V6 V6 
D G4 G4 G4 G5 G5 G5 G6 G6 G6 D5 D5 D5 
E D6 D6 D6 D7 D7 D7 D8 D8 D8 D9 D9 D9 
F DG2 DG2 DG2 DG4 DG4 DG4 DG5 DG5 DG5 DG7 DG7 DG7 
G             
H             
Stellenbosch University  https://scholar.sun.ac.za
128 
 
• Set up of plate 2:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 2 2 2 3 3 3 4 4 4 
B 5 5 5 6 6 6 V1 V1 V1 V2 V2 V2 
C V3 V3 V3 V4 V4 V4 G1 G1 G1 G3 G3 G3 
D G4 G4 G4 D1 D1 D1 D2 D2 D2 D3 D3 D3 
E D4 D4 D4 DG1 DG1 DG1 DG2 DG2 DG2 DG3 DG3 DG3 
F DG4 DG4 DG4 DG5 DG5 DG5       
G             
H             
• Added 50 µl of standards into standard wells  
• Added 35 µl of sample and 15 µl of phosphate buffer into sample wells (0.5 X 
dilution) 
• Added 50 µl DTNB using a multichannel into all wells 
• Added 50 µl GR using a multichannel into all wells 
•  At the plate reader machine, added 50 µl of NADPH using a multichannel into all 
wells 
• Placed plate immediately into the MultiskanTM Spectrum microplate 
spectrophotometer (51119200, Thermo Fisher Scientific, Massachusetts, USA). 
• Read plate every 30 seconds for 5 minutes at 412 nm using  
For GSSG: 
Method:  
• The centrifuge tubes were thawed on ice and then centrifuged at 14 000 rpm 
(16 000 x g) for 10 minutes at 4 °C 
• GSSG standards were prepared as follows: 
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Tube GSSG (μl)) Buffer A (μl)) 
(Blank) 1 0 1000 
2 167 833 
3 334 667 
4 500 500 
5 667 334 
6 833 167 
 
• Set up of plate 1:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 2 2 2 3 3 3 4 4 4 
B 5 5 5 6 6 6 C5 C5 C5 C6 C6 C6 
C C7 C7 C7 V4 V4 V4 V5 V5 V5 V6 V6 V6 
D G4 G4 G4 G5 G5 G5 G6 G6 G6 D5 D5 D5 
E D6 D6 D6 D7 D7 D7 D8 D8 D8 D9 D9 D9 
F DG2 DG2 DG2 DG4 DG4 DG4 DG5 DG5 DG5 DG7 DG7 DG7 
G             
H             
• Set up of plate 2:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 2 2 2 3 3 3 4 4 4 
B 5 5 5 6 6 6 V1 V1 V1 V2 V2 V2 
C V3 V3 V3 V4 V4 V4 G1 G1 G1 G3 G3 G3 
D G4 G4 G4 D1 D1 D1 D2 D2 D2 D3 D3 D3 
E D4 D4 D4 DG1 DG1 DG1 DG2 DG2 DG2 DG3 DG3 DG3 
F DG4 DG4 DG4 DG5 DG5 DG5       
G             
H             
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• Added 50 µl of standards into standard wells 
• Added 50 µl of sample into sample wells  
• Added 50 µl of DTNB using a multichannel into all wells 
• Added 50 µl of GR using a multichannel into all wells 
•  At the plate reader machine, added 50 µl of NADPH using a multichannel into all 
wells 
• Placed plate immediately into the MultiskanTM Spectrum microplate 
spectrophotometer (51119200, Thermo Fisher Scientific, Massachusetts, USA).  
• Read plate every 30 seconds for five minutes at 412 nm  
APPENDIX M: Conjugated Dienes (CDs) assay 
Reagents: 
• Chloroform (102444, Merck Millipore, Massachusetts, USA) 
• Methanol (106007, Merck Millipore, Massachusetts, USA) 
• Cyclohexane (102822, Merck Millipore, Massachusetts, USA) 
Method:  
• The centrifuge tubes were thawed on ice  
• 200 µl of homogenate was transferred into a new centrifuge tube 
• 450 µl of chloroform and methanol solution (2:1 ratio) was added to each centrifuge 
tube 
• 150 µl of distilled water was added to each centrifuge tube and vortexed 
• Centrifuge tubes were centrifuged at 12 000 rpm (13 300 x g) at 4 °C for 10 minutes 
to separate the phases  
• 150 µl of bottom chloroform layer was removed and transferred into a new 
centrifuge tube 
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• Centrifuge tubes were left open to dry at 4 °C overnight 
• The residue was reconstituted with 750 µl cyclohexane (102822, Merck Millipore, 
Massachusetts, USA) and vortexed  
• Set up of plate 1:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank Blank V4 V4 V4 V5 V5 V5 V6 V6 V6 
B G4 G4 G4 G5 G5 G5 G6 G6 G6 D5 D5 D5 
C D6 D6 D6 D7 D7 D7 D8 D8 D8 D9 D9 D9 
D DG2 DG2 DG2 DG4 DG4 DG4 DG5 DG5 DG5 DG7 DG7 DG7 
E V1 V1 V1 V2 V2 V2 V3 V3 V3 V4 V4 V4 
F G1 G1 G1 G3 G3 G3 G4 G4 G4 D2 D2 D2 
G D3 D3 D3 D4 D4 D4 DG1 DG1 DG1 DG2 DG2 DG2 
H DG3 DG3 DG3 DG4 DG4 DG4 DG5 DG5 DG5    
 
• Added 200 µl of cyclohexane into blank wells 
• Added 200 µl of sample into sample wells  
• Placed plate into the MultiskanTM Spectrum microplate spectrophotometer 
(51119200, Thermo Fisher Scientific, Massachusetts, USA) 
• Read absorbance at 234 nm  
APPENDIX N: Thiobarbituric Acid Reactive Substances (TBARS) Assay 
Reagents for TBARS assay: 
• 0.1 M Sodium hydroxide (NaOH, S5881, Sigma-Aldrich, St Louis, USA): 
o Added 250 µl of NaOH in 10 ml of distilled water 
• 2-Thiobarbituric acid (TBA, T5500, Sigma-Aldrich, St Louis, USA):  
o Weighed 0.125 g and dissolved in 10 ml of NaOH  
• Butylated hydroxytroluene (BHT, B1378, Sigma-Aldrich, St Louis, USA): 
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o Added 0.008 g of BHT in 10 ml of 96% ethanol (16368, Sigma-Aldrich, St 
Louis, USA)  
• 14.6 M Ortho-phosphoric acid (OPA, 100573, Merck Millipore, Massachusetts, 
USA) 
o Added 684.93 µl OPA to 50 ml distilled water 
• Saturated salt solution 
o A falcon tube was filled to three quarters full and distilled water was added 
o Solution was shaken until the salt was not completely dissolved after 
approximately two minutes of shaking 
Method:  
• The centrifuge tubes were thawed on ice and then centrifuged at 14 000 rpm 
(16 000 x g) for 10 minutes at 4 °C  
• Centrifuge tubes were labelled, and holes were punctured into the lids 
• Added 50 µl of sample to each tube 
• Added 6.25 µl of 4 mM BHT solution to each tube 
• Added 50 µl of 0.2 M OPA solution to each tube 
• Added 6.25 µl of 0.11 M TBA to each tube 
• The tubes were placed in a 90 °C waterbath for 45 minutes  
• The tubes were cooled immediately in an ice bath 
• Added 50 µl of saturated salt solution to each tube 
• Added 1000 µl of butanol to each tube 
• The tubes were centrifuged at 14 000 rpm (16 000 x g) for 20 seconds, during 
which the solution in the tubes were separated into two layers. The top layer had a 
slight pink colour. This is known as the butanol phase 
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• Set up of plate:  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Blan
k 
Blan
k 
Blan
k 
C5 C5 C5 C6 C6 C6 C7 C7 C7 
B V4 V4 V4 V5 V5 V5 V6 V6 V6 G4 G4 G4 
C G5 G5 G5 G6 G6 G6 D5 D5 D5 D6 D6 D6 
D D7 D7 D7 D8 D8 D8 D9 D9 D9 DG2 DG2 DG2 
E DG4 DG4 DG4 DG5 DG5 DG5 DG7 DG7 DG7    
F             
G             
H             
 
• Added 300 µl of butanol into blank wells 
• Added 300 µl of butanol phase into sample wells 
• Placed plate into the MultiskanTM Spectrum microplate spectrophotometer 
(51119200, Thermo Fisher Scientific, Massachusetts, USA) 
• Read absorbance at 532 nm 
APPENDIX O: Western blotting protocol 
Preparation of lysates: 
• Stored the harvested tissues at - 80 °C in labelled centrifuge tubes 
• Each pancreas was carefully crushed using a sterile mortar and pestle on ice and 
separated into chilled centrifuge tubes 
• 300 µl of modified radio-immunoprecipitation (RIPA) buffer was added to each 
centrifuge tube 
• Contents of each centrifuge tube were homogenised on ice, in an attempt to avoid 
heating of the contents 
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• After homogenisation, the centrifuge tubes were left on ice for an hour to allow for 
the froth to settle 
• Once the froth had settled, the centrifuge tubes were centrifuged at 14 000 rpm 
(16 000 x g) at 4 °C for an hour 
• The supernatant was transferred to new centrifuge tubes and centrifuged again at 
14 000 rpm (16 000 x g) at 4 °C for 15 minutes 
• The supernatant was removed again and transferred to a new centrifuge tube 
• Protein content was determined using Direct DetectTM Infrared Spectrometer 
(DDHW00010-WW, Merck Millipore, Massachusetts, USA, Massachusetts, USA), 
where RIPA buffer was used as the blank 
• The lysates were diluted accordingly with Laemmli’s solution and RIPA buffer into 
centrifuge tubes, in which a hole was punched into each lid. Laemmli’s solution 
was prepared as follows: 850 µl Laemmli’s Sample Buffer and 150 µl of 2-
mercaptoethanol 
• The prepared lysates were boiled at 95 °C for five minutes and stored at - 80 °C 
until required 
Preparation and assembly of gels and loading tank: 
• On the day of experiment, the prepared lysates were thawed on ice 
• The thawed lysates were boiled at 95 °C for five minutes, and then centrifuged at 
9 300 rpm (8000 x g) for 10 seconds and placed back on ice 
• 1 mm plates (10 wells) (Biorad, Johannesburg, South Africa) were cleaned with 
70% ethanol spray 
• The plates were assembled into the cassette. Distilled water was used to check for 
leaks. 
• For the 12% gels, used a clean Pasteur pipette to pour the prepared resolving gel 
between the two plates at one corner to avoid making bubbles. Immediately, the 
stacking gel was then poured on top of the resolving gel in the same manner with 
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a clean Pasteur pipette, and the 10 well comb (Biorad, Johannesburg, South 
Africa) was inserted perpendicular to the plates to avoid forming bubbles. The gel 
was allowed to set for approximately an hour 
• For the 15% gels, the prepared resolving gel was poured between the two plated 
at one corner to avoid making bubbles using a clean Pasteur pipette. 100% ethanol 
was then poured on top and the resolving gel was allowed to set at room 
temperature for approximately an hour. Once the resolving gel had set, the ethanol 
was poured off and plates were dabbed dry. Another clean Pasteur pipette was 
used to pour the prepared stacking gel on top of the resolving gel in the same 
manner as the resolving gel and the 10 well comb (Biorad, Johannesburg, South 
Africa) was inserted perpendicular to the plates to avoid forming bubbles. The gel 
was allowed to set for approximately 30 minutes 
• Once the gel had set, the plates were removed from the cassette and placed into 
a U-shaped adaptor ensuring that the short plates face inwards, which was then 
placed into loading tank 
• 10 X running buffer was poured into the tank and filled to the top of the plates 
• The comb was removed carefully and perpendicular to the plates 
• A syringe was used to flush and clean out each well with 10 X running buffer 
Loading the protein samples: 
• A flexible loading tip was used and loaded 4 µl of BLUeye Prestained Protein 
Ladder (PM007-0500, GeneDireX, Inc., Beijing, China) into the first well of the gel 
• The samples were loaded into the remaining wells using a new tip for each sample 
• Once all the samples were loaded, the lid was placed on the tank ensuring the 
electrode colours matched up (black on black, and red on red) 
• Connected the wires to the electrophoresis machine and ensured that the wires 
were connected correctly (black in black, and red in red) 
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For the 12% gels: 
• The samples ran at 100V, 400 mA for 10 minutes to allow for the samples to 
migrate through the stacking gel 
• After 10 minutes, the samples ran at 150V, 400 mA until smallest standard of 
protein marker reached the bottom of the gel (about an hour) 
For the 15% gels: 
• The samples ran at 100V, 400 mA until smallest standard of protein marker 
reached the bottom of the gel (about 80 minutes) 
Transferring protein from gel to membrane: 
•  Assembled the Trans-Blot® Turbo™ Mini PVDF Transfer Packs (Biorad, 
Johannesburg, South Africa) 
o Soaked the blotting paper in transfer buffer 
o Soaked the LF PVDF membrane in methanol (1.06007.2500, Merck 
Millipore, Massachusetts, USA) for 30 seconds, and then soaked in transfer 
buffer for two to three minutes 
• Placed the “bottom” blotting paper into the cassette using the TransBlot® Turbo™ 
Transfer System (Biorad, Johannesburg, South Africa) and then the membrane on 
top of the blotting paper. Rolled out any bubbles with mini roller 
• Carefully removed the gel from the plates and activated it using ChemiDoc™ XRS+ 
System with the Image Lab™ Software (Bio-Rad, Johannesburg, South Africa) 
• Once the gel had been activated, it was carefully placed on top of the membrane 
in the cassette. Rolled out any bubble with mini roller 
• Placed the “top” blotting paper on top of the gel in the cassette. Rolled our any 
bubbles with mini roller 
• Closed and locked the cassette, and placed into the transfer machine 
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For 12% gels: 
• Set system to transfer for seven minutes at 15 V 
For 15% gels: 
• Set system to transfer for 10 minutes at 15 V 
• Once the protein transfer was complete, a stain-free blot image of the membrane 
was taken using the ChemiDoc™ XRS+ System with the Image Lab™ Software 
(Bio-Rad, Johannesburg, South Africa) to ensure protein had transferred to the 
membrane 
• The membrane was then rinsed in methanol (1.06007.2500, Merck Millipore, 
Massachusetts, USA), air dried, and then rinsed back in methanol to ensure the 
protein was fixed to the membrane 
• The membrane was washed with 1 X TBS-T (Tris Buffered Saline-Tween Solution) 
three times for five minutes 
• The membrane was blocked in 5% milk solution for an hour on shaker at a gentle 
speed 
• The membranes were washed with 1 X TBS-T three times for five minutes 
Preparation of antibodies: 
• Made up each primary antibody solution in a clean falcon tube  
• Placed the membrane inside the falcon tube by rolling the membrane and ensured 
the “top” of the membrane was facing inward 
• Placed the falcon tubes on rotator in 4 °C fridge overnight 
• The membrane was washed with 1 X TBS-T three times for five minutes 
• Made up the appropriate secondary antibody solution in a clean falcon tube  
• Placed the membrane inside the falcon tube by rolling the membrane and ensuring 
the “top” of the membrane was facing inward 
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• The falcon tube was rolled on a roller at room temperature for an hour 
• The membrane was washed with 1 X TBS-T three times for five minutes 
Exposing with BioRad ChemiDoc™ 
• Made up ClarityTM Western ECL Substrate (1705061, Bio-Rad, Johannesburg, 
South Africa) in a falcon tube that was wrapped in tinfoil (light-sensitive) 
• Turned off the lights in the room 
• Pipetted ECl on area of membrane where protein is expected to be (used protein 
ladder as a guide) 
• Rolled the ECL with mini roller to ensure an even distribution over membrane 
• Exposed the membrane using the ChemiDoc™ XRS+ System with the Image 
Lab™ Software (Bio-Rad, Johannesburg, South Africa) until protein bands 
appeared. A stain-free blot image was then taken for protein normalisation 
Stripping membranes:  
• The membrane was washed in Paul’s Stripping Buffer (Appendix I) twice for 10 
minutes 
• The membrane was washed in distilled water twice for five minutes  
• The membrane was blocked in 5% milk solution for an hour at a gentle speed 
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Preparation of both the primary and secondary antibodies with their appropriate 
dilutions: 
Primary Antibody Company Dilution 
Molecular 
Weight 
Caspase 3 
 
CST (9662) 1:1000 17, 19, 35 
SOD1 (Cu/Zn SOD) 
 
CST (71G8) 1:1000 18 
SOD2 (Mn SOD) 
 
CST (13141) 1:1000 22 
Secondary 
Antibody 
  
HRP-Linked 
 
CST (7074) 1:10 000 
HRP-Linked CST (7076S) 1:10 000 
 
APPENDIX P: Western Blotting reagents and polyacrylamide gel preparations 
RIPA Buffer: 
• Prepared 50 mM Tris-HCl: 
o Added 790 mg Tris (648310, Merck Millipore, Massachusetts, USA) to 75 
ml distilled water 
o Added 900 mg NaCl and stir solution until all solids are dissolved. 
o Used HCl, adjust pH to 7.4.  
o Poured into 100 ml beaker  
• Prepared 10% NP-40: 
o Wrapped small beaker in tinfoil 
o Dissolved 10 ml NP-40 (Nonidet P 40) (74385, Sigma-Aldrich, St Louis, 
USA) into 90 ml distilled water 
o Placed a stirrer in beaker and placed beaker on heated magnetic stirrer until 
completely dissolved 
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• Added 10 mL of prepared 10% NP-40 to prepared 50 mM Tris-HCl 
• Added 2.5 ml of 10 % Na-deoxycholate (D6750, Sigma-Aldrich, St Louis, USA) and 
stir until solution is clear 
• Added 1 ml of 100 mM EDTA (Ethylenediaminetetraacetic acid) (EDS, Sigma-
Aldrich, St Louis, USA) and adjusted final volume of solution to 100 ml with distilled 
water 
Working RIPA: 
• For every 1 ml of RIPA added 
o 1 µg/ml leupeptin 
o 10 µg/ml pepstatin 
o 1 µg/ml aprotonin 
o 10 µl phenylmethylsulfonyl fluoride (PMSF, 93482, Sigma-Aldrich, St 
Louis, USA) 
o 1 mM activated sodium orthovanadate (Na3VO4, S6508, Sigma-Aldrich, St 
Louis, USA) 
o 1 mM sodium fluoride (NaF) (106449, Merck Millipore, Massachusetts, 
USA) 
Laemmli’s Sample Buffer: 
Stock solution: 
• Prepared 0.5 M Tris-HCl (pH 6.8): 
o Weighed 30.285 g of Tris (648310, Merck Millipore, Massachusetts, USA) 
in a small glass beaker 
o Added 400 ml of distilled water 
o Adjusted pH to 6.8 
o Adjusted final volume to 500 ml with distilled water 
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• Prepared 10 % Sodium dodecyle sulfate (SDS) 
o Weighed 5 g of SDS (L3771, Sigma-Aldrich, St Louis, USA) in a small glass 
beaker 
o Added 50 ml of distilled water and stir to dissolve 
• Dissolved in 38 ml distilled water: 
o 10 ml 0.5 M Tris-HCl (pH 6.8) 
o 8 ml glycerol (SAAR2676520, Merck Millipore, Massachusetts, USA) 
o 16 ml 10% sodium SDS (L3771, Sigma-Aldrich, St Louis, USA) 
o 4 ml 0.05% (w/v) Bromophenol blue (SAAR1437500CB, Merck Millipore, 
Massachusetts, USA) 
Working solution of Laemmli’s solution 
• For every 850 μl of Laemmli’s Buffer Stock Solution, added 150 μl of β-
mercaptoethanol  
10 X TBS: 
• Dissolved in 600 ml distilled water: 
o 4.2 g Tris (648310, Merck Millipore, Massachusetts, USA)  
o 80 g NaCl (1.06404, Merck Millipore, Massachusetts, USA)  
o Adjusted pH to 7.6 
o Adjust final volume to 1 L 
1 X TBS-T 
• Mixed together: 
o 200 ml of 10 X TBS  
o 1800 ml distilled water  
o 2 ml Tween20 (P9416, Sigma-Aldrich, St Louis, USA) 
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Running Buffer: 
• Mixed together: 
o 200 ml of 10 X TGS (Tris/Glycine/SDS Buffer, 161-0772, BioRad, 
Johannesburg, South Africa) 
o 1800 ml distilled water 
Paul’s Stripping Buffer: 
• Dissolved in 400 ml distilled water: 
o 7.5 g glycine (357002-1KG, Merck Millipore, Massachusetts, USA) 
o 0.5 g SDS (L3771, Sigma-Aldrich, St Louis, USA) 
o 5 ml Tween20 (P9416, Sigma-Aldrich, St Louis, USA) 
• Adjusted pH to 2.2 
• Adjusted final volume to 500 ml 
5% fat-free milk solution: 
• Mix together: 
o 5 ml fat-free milk 
o 95 ml 1 X TBS-T 
Preparation of stain-free acrylamide gels: 
For 12% Gels:  
• TGX Stain-Free™ Fastcast™ Acrylamide Solutions (161-0185, Biorad, 
Johannesburg, South Africa) was used to make up gels. All instructions in the kit 
were followed when making up gels 
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For 15% Gels (enough for 2 gels) 
15% gel constituent (Resolving Gel) 
Distilled water 5.245 ml 
40% Acrylamide solution (100638, 
Merck Millipore, Massachusetts, USA)  
5.62 5ml 
1.5M Tris-HCl (pH 8.8) 3.75 ml 
10% w/v SDS  150 µl 
10% w/v APS  150 µl 
TCE (T54801, Sigma-Aldrich, St Louis, 
USA) 
75 µl 
TEMED (add last) (1.10732.0100, 
Merck Millipore, Massachusetts, USA) 
6 µl 
 
4% gel constituent (Stacking Gel) 
Distilled water 4.84 ml 
40% Acrylamide solution (100638, 
Merck Millipore, Massachusetts, USA) 
1 ml 
1.5M Tris-HCl (pH 8.8) 2 ml 
10% w/v SDS  80 µl 
10% w/v APS 80 µl 
TEMED (add last) (1.10732.0100, 
Merck Millipore, Massachusetts, USA) 
8 µl 
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Membranes of representative images for Western blotting: 
 
Left: Membrane with protein     Right: Total Protein 
 
SOD1: Ladder,V,V,G,D,DG,V,G,D,DG 
 
 
 
 
 
 
SOD2: Ladder,V,V,G,D,DG,V,D,D,DG 
 
 
 
 
 
Total & Cleaved caspase-3: Ladder,V,G,D,DG,V,D,D,DG 
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